var title_f1_42_1696="Gastroschisis 3D ultrasound";
var content_f1_42_1696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastroschisis 3D ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a 3-dimensional ultrasound examination of a fetus with a gastroschisis at 16 weeks of gestation. The free loops of bowel are seen floating in the amniotic fluid. The umbilical cord is seen superior and to the left of the defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1696=[""].join("\n");
var outline_f1_42_1696=null;
var title_f1_42_1697="Bullae in alpha 1 AT";
var content_f1_42_1697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe bullous disease in alpha-1 antitrypsin deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large bilateral subpleural bullae lead to retraction of the underlying normal lung parenchyma. The bullae have an increased compliance and allow normal lung to retract according to its intrinsic elastic recoil. The bullae are not under tension; their effect is similar to that of a pneumothorax (\"intrapulmonary pneumothorax\").",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1697=[""].join("\n");
var outline_f1_42_1697=null;
var title_f1_42_1698="Blunt cerebrovascular injury algorithm";
var content_f1_42_1698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 639px\">",
"   <div class=\"ttl\">",
"    Blunt cerebrovascular injury algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 619px; height: 617px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BCVI: blunt cerebrovascular injury; OR: operating room; TIA: transient ischemic attack; GCS: Glasgow coma scale; CT: computed tomography; CTA: computed tomographic angiography; MRI: magnetic resonance imaging; PTT: partial thromboplastin time; CHI: closed head injury; DAI: diffuse axonal injury; MS: mental status.",
"     <br/>",
"     * For positive arteriogram, follow treatment algorithm as per 16-slice CTA results (E and F).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     CT angiography with multidetector-row CT, 16-channel or higher. If fewer than 16 channels, interpret CTA with caution.",
"     <br/>",
"     &Delta; If signs/symptoms or high clinical suspicion and (-)CTA, consider arteriogram as the gold standard.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     If Grade II-V injury is surgically accessible and patient has not suffered completed stroke, pursue operative repair.",
"     <br/>",
"     &sect; Heparin is preferred in the acute setting, as it is reversible and may be more efficacious than antiplatelet drugs. Anticoagulation may be contraindicated due to other injuries.",
"     <br/>",
"     &yen; Stenting should be performed with caution, and appropriate antithrombotic therapy administered concurrently.",
"     <br/>",
"     &Dagger; Aspirin alone (75-150 mg daily) is adequate and should be considered lifelong as its risk profile is superior to coumadin.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Biffl WL, Cothren CC, Moore EE, et al. Western Trauma Association critical decisions in trauma: screening for and treatment of blunt cerebrovascular injuries. J Trauma 2009; 67:1150. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1698=[""].join("\n");
var outline_f1_42_1698=null;
var title_f1_42_1699="Mild episcleritis";
var content_f1_42_1699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mild episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J. Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1699=[""].join("\n");
var outline_f1_42_1699=null;
var title_f1_42_1700="ADA management patients HHS";
var content_f1_42_1700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Protocol for the management of adult patients with HHS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 628px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HHS diagnostic criteria: serum glucose &gt;600 mg/dl, arterial pH &gt;7.3, serum bicarbonate &gt;15 mEq/l, and minimal ketonuria and ketonemia. Normal laboratory values vary; check local lab normal ranges for all electrolytes.",
"    <div class=\"footnotes\">",
"     IV: intravenous; SC: subcutaneous.",
"     <br>",
"      * After history and physical exam, obtain capillary glucose and serum or urine ketones (nitroprusside method). Begin one liter of 0.9 percent NaCl over one hour and draw arterial blood gases, complete blood count with differential, urinalysis, serum glucose, BUN, electrolytes, chemistry profile and creatinine levels STAT. Obtain electrocardiogram, chest X-ray, and specimens for bacterial cultures, as needed.",
"      <br>",
"       &bull; Serum Na",
"       <sup>",
"        +",
"       </sup>",
"       should be corrected for hyperglycemia (for each 100 mg/dl glucose &gt;100 mg/dl, add 1.6 mEq to sodium value for corrected serum sodium value).",
"       <br>",
"        &Delta; An alternative IV insulin regimen is to give a continuous intravenous infusion of regular insulin at 0.14 units/kg per hour; at this dose, an initial intravenous bolus is not necessary.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2006 American Diabetes Association From Diabetes Care Vol 29, Issue 12, 2006. Modifications from Diabetes Care Vol 32, Issue 7, 2009. Reprinted with permission from the American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1700=[""].join("\n");
var outline_f1_42_1700=null;
var title_f1_42_1701="Map of affected states PI";
var content_f1_42_1701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 633px\">",
"   <div class=\"ttl\">",
"    Map of states where contaminated steroid medicine was distributed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 613px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The states shown in blue had healthcare facilities that got the contaminated medicine. But the facilities in Nevada that got the contaminated medicine never used it on anyone. If you got a steroid injection in Nevada, you do not need to worry.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs): Map of Healthcare Facilities which Received Three Lots of Methylprednisolone Acetate (PF) Recalled from New England Compounding Center on September 26, 2012. Available at:",
"     <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html\" target=\"_blank\">",
"      file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html",
"     </a>",
"     (Accessed October 11, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1701=[""].join("\n");
var outline_f1_42_1701=null;
var title_f1_42_1702="Intestinal sinonasal CA Light";
var content_f1_42_1702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intestinal-type sinonasal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph showing the anastamosing cords of columnar cells with interspersed goblet cells, resembling colonic carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of D. Solt, DMD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1702=[""].join("\n");
var outline_f1_42_1702=null;
var title_f1_42_1703="Sickle cell anemia";
var content_f1_42_1703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral blood smear in sickle cell anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Peripheral blood smear from a patient with sickle cell anemia. This smear shows multiple sickle cells (blue arrows). There are also findings consistent with functional asplenia, including a nucleated red blood cell (upper left), a red blood cell containing a Howell-Jolly body (black arrow), and target cells (red arrow).",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1703=[""].join("\n");
var outline_f1_42_1703=null;
var title_f1_42_1704="Oral appliances in the treatment of obstructive sleep apnea in adults";
var content_f1_42_1704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral appliances in the treatment of obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1704/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1704/contributors\">",
"     Peter A Cistulli, MBBS, PhD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1704/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1704/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1704/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/42/1704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a disorder that is characterized by obstructive apneas and hypopneas due to repetitive collapse of the upper airway during sleep. The concept of using an oral appliance to relieve upper airway obstruction was first reported in the 1930s and applied to OSA approximately 20 years ago. There has been increasing interest in oral appliances in recent years because of the high prevalence of OSA and recognition of the limitations of positive airway pressure therapy (eg, frequent nonadherence) and surgical therapy.",
"   </p>",
"   <p>",
"    The management of patients with OSA using an oral appliance is reviewed here. Relevant definitions and the treatment of OSA using other modalities (eg, continuous positive airway pressure) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multidisciplinary approach is required to manage a patient who has OSA with an oral appliance. This begins with a medical assessment and sleep study to confirm the diagnosis of OSA, determine whether treatment is indicated, and, if so, whether an oral appliance is appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1\">",
"     1",
"    </a>",
"    ]. Dental evaluation follows, which includes assessment of suitability for oral appliance therapy, device selection, and fitting.",
"   </p>",
"   <p>",
"    Once oral appliance therapy is initiated, the effectiveness should be evaluated by objective testing, since subjective assessment alone is often unreliable. Long-term follow-up should be performed by both a medical and a dental clinician. This approach is described in this section and outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57453 \" href=\"UTD.htm?27/4/27727\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of OSA should be confirmed and its severity determined prior to the initiation of therapy with an oral appliance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Disease severity guides the selection of patients for treatment by identifying those who are at greatest risk for developing complications of OSA. It also provides a baseline from which to measure the effectiveness of therapy. The diagnostic approach to OSA in adults is described in detail separately and shown in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been confirmed that a patient has OSA and the severity of the OSA measured, it must be determined whether treatment is indicated and, if so, whether an oral appliance is an appropriate modality. Indications for the treatment of OSA and selection of an appropriate modality are discussed in detail separately (",
"    <a class=\"graphic graphic_algorithm graphicRef70443 \" href=\"UTD.htm?25/58/26541\">",
"     algorithm 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Indications for treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Choosing a therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral appliances are appropriate for patients with any of the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild to moderate OSA, defined as an apnea hypopnea index (AHI, the number of apneas and hypopneas per hour of sleep) of 5 to 30 events per hour. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment beyond behavior modification is indicated. Behavior modification refers to weight loss, abstinence from alcohol, etc.",
"     </li>",
"     <li>",
"      Preference for an oral appliance, rather than positive airway pressure therapy.",
"     </li>",
"     <li>",
"      Non-adherence with positive airway pressure therapy, non-responsiveness to such therapy, or refusal of such therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral appliances are most appropriate for patients with mild or moderate OSA because they may be less effective in patients with severe OSA (ie, AHI &gt;30",
"    <span class=\"nowrap\">",
"     events/hour).",
"    </span>",
"    Patients with severe OSA usually receive positive airway pressure as first-line therapy, although severe OSA is not an absolute contraindication to oral appliances (successful treatment has been reported) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. For patients with severe OSA who begin positive airway pressure therapy and either do not adhere to it or want to change to an oral appliance, efforts should be directed toward improving adherence with positive airway pressure therapy before switching to an oral appliance.",
"   </p>",
"   <p>",
"    Upper airway surgery may be preferable to oral appliances in patients who have an upper airway obstruction that is causing the OSA (eg, tonsillectomy, adenoidectomy) and can be ameliorated surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may prefer oral appliances over positive airway pressure because they are easier to use, more easily portable, quiet, and do not require a power source [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/3\">",
"     3",
"    </a>",
"    ]. Oral appliances may also be a useful substitute for positive airway pressure during travel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several clinical situations in which oral appliances should not be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in whom rapid initiation of treatment is desirable (eg, patients with severe symptomatic OSA, sleepiness while driving, severe hypoxemia, or active cardiovascular comorbidities) should be treated with positive airway pressure instead of an oral appliance. The former may be more effective and can be initiated quickly, while the latter requires incremental advancement of the mandible over weeks to months.",
"     </li>",
"     <li>",
"      Severe oxyhemoglobin desaturation (large magnitude or prolonged) should prompt initiation of an alternative therapy (usually positive airway pressure) because oral appliance therapy may induce suboptimal improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dental conditions such as temporomandibular joint disease, periodontal disease, insufficient dentition to support appliance retention in the mouth, and inadequate range of motion of the jaw are relative contraindications and require expert dental assessment prior to consideration of treatment with an oral appliance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1\">",
"       1",
"      </a>",
"      ]. Limited capacity for mandibular protrusion (&lt;6 mm) may also be a contraindication, but the evidence for this is not strong. One study found that 34 percent of patients with OSA may not be suitable candidates for treatment with an oral appliance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Predictors of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not yet possible to reliably identify which patients will benefit from therapy with an oral appliance. The following factors are potential predictors of a better outcome, but none have been prospectively evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild to moderate OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/7\">",
"       7",
"      </a>",
"      ]. Although it seems reasonable to expect increasing severity of OSA to predict treatment failure, this is an imperfect predictor because complete responses have been reported among patients with severe OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Younger age, lower body mass index, and supine OSA, among others (",
"      <a class=\"graphic graphic_table graphicRef80158 \" href=\"UTD.htm?3/17/3355\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain cephalometric variables (eg, shorter soft palate, decreased distance between mandibular plane and hyoid bone), alone or in combination with other anthropomorphic and polysomnographic variables [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A higher ratio of the expiratory to inspiratory flow rate at 50 percent of vital capacity (MEF50:MIF50), as determined from flow-volume curves during pulmonary function testing [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lower nasal resistance, as measured by posterior rhinomanometry [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until the value of the last three predictors are confirmed by prospective investigation, we do NOT recommend routine cephalometry, pulmonary function testing, or rhinomanometry for deciding upon the appropriateness of oral appliance therapy in patients with OSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Device selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major types of oral appliances are mandibular advancement splints and tongue retaining devices:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mandibular advancement splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mandibular advancement splints (MAS, also called mandibular repositioning appliances) are the most commonly used oral appliances. They are anchored to the dental arches and induce mandibular advancement (ie, protrusion), resulting in several beneficial anatomical changes. These changes can include anteroposterior and lateral retrolingual and velopharyngeal enlargement, resulting in increased cross-sectional areas and upper airway volume (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75893 \" href=\"UTD.htm?28/3/28726\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    MAS differ in configuration (ie, one or two pieces), size, material, degree of customization to a patient's dentition, coupling mechanism (ie, the method by which two pieces connect), occlusal coverage (ie, coverage of the surfaces of the teeth that contact each other when the mouth is closed), ability to titrate the mandibular advancement, amount of mandibular mobility permitted, and amount of oral respiration permitted (",
"    <a class=\"graphic graphic_picture graphicRef52099 graphicRef64842 graphicRef75613 \" href=\"UTD.htm?29/56/30597\">",
"     picture 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two-piece MAS allow more mandibular movement and have a greater range of settings than one-piece MAS. As a result, they tend to be most comfortable.",
"     </li>",
"     <li>",
"      MAS that maintain mandibular advancement while permitting lateral jaw movement, jaw opening, or jaw closing may reduce the risk of complications and achieve better patient acceptance, although some clinicians believe the amount of vertical opening should be minimized.",
"     </li>",
"     <li>",
"      Custom-fitted MAS are preferable to self-administered over-the-counter (ie, boil and bite) varieties because they appear to be more effective and are more likely to be retained by both the upper and lower teeth, insuring that the lower jaw does not fall out of the appliance during sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Full occlusal coverage may be desirable to distribute the dental forces associated with mandibular advancement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tongue retaining devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tongue retaining devices use a suction cavity to pull the tongue out of the mouth, thus improving retrolingual dimensions (",
"    <a class=\"graphic graphic_picture graphicRef68697 \" href=\"UTD.htm?33/45/34527\">",
"     picture 2",
"    </a>",
"    ). These devices have not been well studied. One clear advantage is that they can be used in edentulous patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Comparative efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of evidence comparing the two types of oral appliances. One trial randomly assigned 27 patients with OSA to receive either a MAS or a tongue retaining device for one week [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/12\">",
"     12",
"    </a>",
"    ]. After a one week washout period, the patients then crossed over and used the other device for one week. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no statistically significant difference in the degree to which the two devices reduced the apnea hypopnea index (AHI)",
"     </li>",
"     <li>",
"      There was a trend toward a greater frequency of complete and partial improvement in the AHI and symptoms with the MAS compared to the tongue retaining device",
"     </li>",
"     <li>",
"      Tolerance and compliance were better with the MAS",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Device titration",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAS need to be titrated. The amount of advancement required for a clinical response generally ranges from 50 to 90 percent of the maximum protrusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/13\">",
"     13",
"    </a>",
"    ]. However, this can vary substantially among individuals, with some patients failing treatment regardless of the degree of advancement. There is as yet no reliable clinical method of determining the amount of advancement needed. The titration process is based on clinical response over a period of weeks and months, followed by polysomnography or a suitable surrogate (eg, level 3 portable monitoring). Patient tolerance is a major determinant of the extent and speed of advancement that is feasible. For most patients, tolerance increases with time.",
"   </p>",
"   <p>",
"    Single-night titration is a promising approach whose practical application remains to be determined. It involves incrementally advancing the mandible under technician supervision while the patient sleeps [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Single-night titration of an oral appliance during polysomnography was evaluated by two observational studies, which found that the approach successfully identified the target amount of mandibular advancement. In a randomized trial, single-night titration of an oral appliance followed by ongoing oral appliance therapy was compared to single-night titration of continuous positive airway pressure (CPAP) followed by ongoing CPAP therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/16\">",
"     16",
"    </a>",
"    ]. Both approaches improved subjective and objective outcomes over two months, including sleepiness, neurocognitive function, and quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the dentist has completed the titration of MAS therapy, patients should generally be reevaluated by someone with expertise in the treatment of sleep disorders soon after, in order to assess the clinical and polysomnographic efficacy of treatment. This consists of asking whether the symptoms of OSA have resolved and by performing full polysomnography or level 3 portable monitoring with the oral appliance in place [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Subjective measures alone are insufficient to assess efficacy because oral appliance therapy may be associated with a placebo effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dental follow-up every six months for one year and annually thereafter is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The purpose of dental evaluation is to monitor for comfort, adherence, device deterioration, device maladjustment, bite changes, occlusion integrity, and symptoms or signs of recurrent OSA. Similarly, long-term follow up by someone with expertise in the treatment of sleep disorders is recommended to monitor for recurrent symptoms of OSA or the development of complications of OSA.",
"   </p>",
"   <p>",
"    A decision to continue or discontinue oral appliance therapy may need to be made if adverse dental effects are detected. The decision should balance the magnitude of the adverse effect, the severity of OSA, the response to therapy, and the desirability of treatment alternatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most trials that evaluated oral appliance therapy used mandibular advancement splints (MAS), rather than tongue retaining devices. The effects of MAS on both short-term and long-term outcome measures are reviewed in this section. In addition, clinical outcomes due to MAS are compared to those due to positive airway pressure or surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;MAS reduce the frequency of arousals and respiratory events (eg, apneas and hypopneas) during sleep, while also improving oxyhemoglobin saturation and snoring [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/4,5,7,17\">",
"     4,5,7,17",
"    </a>",
"    ]. These effects were illustrated by a cross-over trial that performed polysomnography on 28 patients with OSA who had been randomly assigned to receive either a MAS or a control device [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/4\">",
"     4",
"    </a>",
"    ]. Compared to the group that received a control device, the group that received a MAS had a better apnea hypopnea index (14 versus 30 events per hour), minimal oxygen saturation (91 versus 87 percent), and arousal index (27 versus 41 events per hour) after one week of treatment.",
"   </p>",
"   <p>",
"    Some studies suggest that complete resolution of OSA, defined as an apnea hypopnea index (AHI) &lt;5 events per hour during treatment, is more likely in patients with mild to moderate OSA (AHI 5 to 30 events per hour) than in patients with severe OSA (AHI &gt;30 events per hour) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. However, this finding has not been universal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Until more definitive data are available, clinicians should preferentially use positive airway pressure as primary therapy in patients with severe OSA because positive airway pressure has consistently demonstrated benefit across multiple trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MAS have also been shown to decrease subjective daytime sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/3,7,17\">",
"     3,7,17",
"    </a>",
"    ]. However, the clinical significance of this finding is uncertain because a placebo-effect has been identified among patients who use oral appliances and the effect on objective daytime sleepiness has not been well studied. One cross-over trial randomly assigned 68 patients with OSA (respiratory disturbance index &ge;10 events per hour plus at least two symptoms or signs of OSA) to receive a MAS or a control device [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/5\">",
"     5",
"    </a>",
"    ]. The MAS induced small but statistically significant improvements in mean sleep latency (10.3 versus 9.1 minutes) and subjective sleepiness (seven versus nine), which were assessed by the Multiple Sleep Latency Test (MSLT) and Epworth Sleepiness Scale, respectively. This trial was supported by a randomized trial that compared oral appliance therapy to continuous positive airway pressure (CPAP) and found that both therapies reduced daytime sleepiness compared to baseline, as assessed by both the Epworth Sleepiness Score and the OSLER test [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=see_link\">",
"     \"Quantifying sleepiness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of MAS on a range of other outcome measures has been evaluated and is the subject of ongoing studies. Studies have reported a small but significant improvement of blood pressure, neurocognitive function, and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/3,18-21\">",
"     3,18-21",
"    </a>",
"    ]. This was best illustrated by a cross-over trial that randomly assigned 61 patients with OSA (AHI &ge;10 events per hour of sleep) to receive a MAS or a control device for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/18\">",
"     18",
"    </a>",
"    ]. MAS treatment significantly reduced the awake mean systolic and diastolic blood pressures, with the peak effect (approximately 3 mmHg) noted during the late sleeping period and early morning. Oral appliances have also been reported to improve driving simulator performance, with a magnitude of effect similar to that seen with CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial effects of MAS persist long-term in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/7,23-25\">",
"     7,23-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study followed 619 consecutive patients with OSA (mean AHI 16 events per hour of sleep) who were treated with MAS for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/25\">",
"       25",
"      </a>",
"      ]. Treatment was successful (defined as an AHI &lt;10",
"      <span class=\"nowrap\">",
"       events/hr)",
"      </span>",
"      at one year in 54 percent of patients. However, 24 percent of patients discontinued their device, primarily due to discomfort.",
"     </li>",
"     <li>",
"      An observational study followed 33 consecutive patients with OSA (mean AHI 22 events per hour of sleep) who were treated with MAS [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/24\">",
"       24",
"      </a>",
"      ]. Among the 19 patients who returned for follow-up at five years, treatment was successful (defined as an AHI &lt;10",
"      <span class=\"nowrap\">",
"       events/hr)",
"      </span>",
"      in 84 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main reasons for long-term relapse of OSA appear to be appliance failure due to wear and tear, as well as weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Compared to positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical trials that compared oral appliances to positive airway pressure (usually CPAP) found that positive airway pressure is superior at improving the AHI and oxyhemoglobin saturation, but not symptoms (eg, daytime sleepiness), the arousal index, or sleep architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/3,16,26-29\">",
"     3,16,26-29",
"    </a>",
"    ]. Patients generally prefer and adhere better to the oral appliance.",
"   </p>",
"   <p>",
"    These findings were illustrated by a meta-analysis of nine randomized trials (440 patients) that compared the effects of CPAP to oral appliances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/30\">",
"     30",
"    </a>",
"    ]. CPAP reduced the AHI, improved sleep efficiency, and attenuated oxyhemoglobin desaturation to a greater degree than oral appliances. However, there was little difference in subjective outcomes, such as sleepiness. Among patients who responded to both therapies, there was strong preference for oral appliances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Compared to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies comparing oral appliances to surgical interventions are scant. In one trial, patients with OSA (AHI 5 to 25 events per hour) were randomly assigned to receive uvulopalatopharyngoplasty (UPPP) or an oral appliance that protruded the mandible to 50 percent of the maximum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/31\">",
"     31",
"    </a>",
"    ]. At one and four years, oral appliance therapy was more likely to normalize the AHI, normalize the apnea index, and achieve a 50 percent reduction in the apnea index.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients experience early side effects, particularly dental discomfort (usually of the upper and lower incisors). Other early side effects include temporomandibular joint pain, dry mouth or excessive salivation, gum irritation, and bruxism (",
"    <a class=\"graphic graphic_table graphicRef64002 \" href=\"UTD.htm?1/26/1451\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/7\">",
"     7",
"    </a>",
"    ]. These side effects are generally mild to moderate in severity and usually last a few weeks or less. It is uncommon for these early side effects to preclude continued use of the oral appliance.",
"   </p>",
"   <p>",
"    Occlusal changes are the major long-term adverse effect of oral appliances. They are characterized by backward movement of the upper front teeth and forward movement of the lower front teeth and mandible, ranging from 0.4 to 3 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Most of the changes occur within the first two years, after which they appear to stabilize. In one observational study of 70 patients with an average follow-up of 7.4 years, occlusal change was identified in 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1704/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occlusal changes are usually minor and do not warrant cessation of treatment. Infrequently, some patients experience larger occlusal changes, necessitating a review of treatment alternatives. It is generally thought that bite changes revert after cessation of the oral appliance. Rarely, permanent abnormalities requiring orthodontic treatment occur. Thus, it is important that patients are fully informed about these risks before commencing treatment. Further research is required to define the factors influencing dentofacial sequelae of long-term treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral appliance therapy should be considered only after the diagnosis of obstructive sleep apnea (OSA) and the need for treatment have been firmly established (",
"      <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef70443 \" href=\"UTD.htm?25/58/26541\">",
"       algorithm 3",
"      </a>",
"      ). The major types of oral appliances are mandibular advancement splints and tongue retaining devices. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Device selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild or moderate OSA who do not express a preference, we suggest positive airway pressure rather than an oral appliance (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is based on the superiority of positive airway pressure (usually continuous positive airway pressure [CPAP]) at reducing the frequency of obstructive events. We define mild to moderate OSA as an apnea hypopnea index (AHI) &le;30 events per hour. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Compared to positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild or moderate OSA who prefer an oral appliance, we suggest an oral appliance rather than positive airway pressure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is based on our recognition that most patients prefer an oral appliance, adherence is an essential aspect of successful treatment, and both modalities are effective compared to no treatment or a sham treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Compared to positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe OSA (AHI &gt;30 events per hour), we suggest that oral appliances NOT be used for routine management (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is based on the variable efficacy of oral appliances reported in this patient population. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Short-term'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most trials that evaluated oral appliance therapy used mandibular advancement splints, rather than tongue retaining devices. Mandibular advancement splints reduce subjective daytime sleepiness, the frequency of respiratory events (eg, apneas and hypopneas) during sleep, and the frequency of arousals. They also improve oxyhemoglobin saturation and snoring. Their effect on objective daytime sleepiness has not been well studied, but they seem to induce a small but significant improvement in blood pressure, neurocognitive function, and quality of life. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral appliances are generally less effective than positive airway pressure at improving the AHI and oxyhemoglobin saturation, although there is no difference in the impact on symptoms (eg, subjective daytime sleepiness) or other health outcomes (eg, blood pressure, neurocognitive function, or quality of life). Patients often prefer oral appliances. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Compared to positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/1\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/2\">",
"      Kushida CA, Morgenthaler TI, Littner MR, et al. Practice parameters for the treatment of snoring and Obstructive Sleep Apnea with oral appliances: an update for 2005. Sleep 2006; 29:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/3\">",
"      Ferguson KA, Cartwright R, Rogers R, Schmidt-Nowara W. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep 2006; 29:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/4\">",
"      Mehta A, Qian J, Petocz P, et al. A randomized, controlled study of a mandibular advancement splint for obstructive sleep apnea. Am J Respir Crit Care Med 2001; 163:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/5\">",
"      Gotsopoulos H, Chen C, Qian J, Cistulli PA. Oral appliance therapy improves symptoms in obstructive sleep apnea: a randomized, controlled trial. Am J Respir Crit Care Med 2002; 166:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/6\">",
"      Petit FX, P&eacute;pin JL, Bettega G, et al. Mandibular advancement devices: rate of contraindications in 100 consecutive obstructive sleep apnea patients. Am J Respir Crit Care Med 2002; 166:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/7\">",
"      Cistulli PA, Gotsopoulos H, Marklund M, Lowe AA. Treatment of snoring and obstructive sleep apnea with mandibular repositioning appliances. Sleep Med Rev 2004; 8:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/8\">",
"      Liu Y, Lowe AA, Fleetham JA, Park YC. Cephalometric and physiologic predictors of the efficacy of an adjustable oral appliance for treating obstructive sleep apnea. Am J Orthod Dentofacial Orthop 2001; 120:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/9\">",
"      Zeng B, Ng AT, Darendeliler MA, et al. Use of flow-volume curves to predict oral appliance treatment outcome in obstructive sleep apnea. Am J Respir Crit Care Med 2007; 175:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/10\">",
"      Zeng B, Ng AT, Qian J, et al. Influence of nasal resistance on oral appliance treatment outcome in obstructive sleep apnea. Sleep 2008; 31:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/11\">",
"      Vanderveken OM, Devolder A, Marklund M, et al. Comparison of a custom-made and a thermoplastic oral appliance for the treatment of mild sleep apnea. Am J Respir Crit Care Med 2008; 178:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/12\">",
"      Deane SA, Cistulli PA, Ng AT, et al. Comparison of mandibular advancement splint and tongue stabilizing device in obstructive sleep apnea: a randomized controlled trial. Sleep 2009; 32:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/13\">",
"      Fleury B, Rakotonanahary D, Petelle B, et al. Mandibular advancement titration for obstructive sleep apnea: optimization of the procedure by combining clinical and oximetric parameters. Chest 2004; 125:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/14\">",
"      P&eacute;telle B, Vincent G, Gagnadoux F, et al. One-night mandibular advancement titration for obstructive sleep apnea syndrome: a pilot study. Am J Respir Crit Care Med 2002; 165:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/15\">",
"      Tsai WH, Vazquez JC, Oshima T, et al. Remotely controlled mandibular positioner predicts efficacy of oral appliances in sleep apnea. Am J Respir Crit Care Med 2004; 170:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/16\">",
"      Gagnadoux F, Fleury B, Vielle B, et al. Titrated mandibular advancement versus positive airway pressure for sleep apnoea. Eur Respir J 2009; 34:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/17\">",
"      Randerath WJ, Verbraecken J, Andreas S, et al. Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J 2011; 37:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/18\">",
"      Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 2004; 27:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/19\">",
"      Barnes M, McEvoy RD, Banks S, et al. Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea. Am J Respir Crit Care Med 2004; 170:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/20\">",
"      Naismith SL, Winter VR, Hickie IB, Cistulli PA. Effect of oral appliance therapy on neurobehavioral functioning in obstructive sleep apnea: a randomized controlled trial. J Clin Sleep Med 2005; 1:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/21\">",
"      Iftikhar IH, Hays ER, Iverson MA, et al. Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med 2013; 9:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/22\">",
"      Hoekema A, Stegenga B, Bakker M, et al. Simulated driving in obstructive sleep apnoea-hypopnoea; effects of oral appliances and continuous positive airway pressure. Sleep Breath 2007; 11:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/23\">",
"      Schmidt-Nowara W, Lowe A, Wiegand L, et al. Oral appliances for the treatment of snoring and obstructive sleep apnea: a review. Sleep 1995; 18:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/24\">",
"      Marklund M, Sahlin C, Stenlund H, et al. Mandibular advancement device in patients with obstructive sleep apnea : long-term effects on apnea and sleep. Chest 2001; 120:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/25\">",
"      Marklund M, Stenlund H, Franklin KA. Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. Chest 2004; 125:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/26\">",
"      Lim J, Lasserson TJ, Fleetham J, Wright J. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev 2004; :CD004435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/27\">",
"      Hoekema A, Stegenga B, De Bont LG. Efficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review. Crit Rev Oral Biol Med 2004; 15:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/28\">",
"      Tan YK, L'Estrange PR, Luo YM, et al. Mandibular advancement splints and continuous positive airway pressure in patients with obstructive sleep apnoea: a randomized cross-over trial. Eur J Orthod 2002; 24:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/29\">",
"      Aarab G, Lobbezoo F, Hamburger HL, Naeije M. Oral appliance therapy versus nasal continuous positive airway pressure in obstructive sleep apnea: a randomized, placebo-controlled trial. Respiration 2011; 81:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/30\">",
"      Giles TL, Lasserson TJ, Smith BJ, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; :CD001106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/31\">",
"      Walker-Engstr&ouml;m ML, Tegelberg A, Wilhelmsson B, Ringqvist I. 4-year follow-up of treatment with dental appliance or uvulopalatopharyngoplasty in patients with obstructive sleep apnea: a randomized study. Chest 2002; 121:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/32\">",
"      Rose EC, Staats R, Virchow C Jr, Jonas IE. Occlusal and skeletal effects of an oral appliance in the treatment of obstructive sleep apnea. Chest 2002; 122:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/33\">",
"      Pantin CC, Hillman DR, Tennant M. Dental side effects of an oral device to treat snoring and obstructive sleep apnea. Sleep 1999; 22:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1704/abstract/34\">",
"      Almeida FR, Lowe AA, Otsuka R, et al. Long-term sequellae of oral appliance therapy in obstructive sleep apnea patients: Part 2. Study-model analysis. Am J Orthod Dentofacial Orthop 2006; 129:205.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7678 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1704=[""].join("\n");
var outline_f1_42_1704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Advantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Predictors of benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Device selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mandibular advancement splints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tongue retaining devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Comparative efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Device titration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Short-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Compared to positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Compared to surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7678|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/4/27727\" title=\"algorithm 1\">",
"      Approach to oral appliances for OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/5/22622\" title=\"algorithm 2\">",
"      OSA diagnosis algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/58/26541\" title=\"algorithm 3\">",
"      OSA treatment algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7678|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/3/28726\" title=\"diagnostic image 1\">",
"      Oral appl induced changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7678|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/19/38206\" title=\"picture 1A\">",
"      Mandibular advance splint I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/27/28094\" title=\"picture 1B\">",
"      Mandibular advan splint II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/31/14832\" title=\"picture 1C\">",
"      Mandibular advan splint III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/45/34527\" title=\"picture 2\">",
"      Tongue retaining device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/17/3355\" title=\"table 1\">",
"      Favorable predict oral devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/26/1451\" title=\"table 2\">",
"      Oral appliance adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_42_1705="Impact of anemia in patients with heart failure";
var content_f1_42_1705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Impact of anemia in patients with heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1705/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/42/1705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is a frequent finding in patients with heart failure (HF), with a prevalence ranging from 4 to 55 percent depending upon the population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/1\">",
"     1",
"    </a>",
"    ]. In an analysis from the SOLVD trial, for example, 22 percent of patients had a hematocrit &le;39 percent and 4 percent had values below 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/2\">",
"     2",
"    </a>",
"    ]. A similar rate of anemia (17 percent) was noted in a population-based cohort of 12,065 patients with newly diagnosed HF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence of anemia appears to increase with worsening functional class (from 9 percent for New York Heart Association [NYHA] class I to 79 percent for class IV in one report) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is increasing evidence that the presence of anemia can worsen cardiac function and enhance symptoms in patients with HF and that correction of anemia may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/5-12\">",
"     5-12",
"    </a>",
"    ]. These issues as well as the causes of anemia in patients with HF will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that may contribute to the development of anemia in patients with HF are discussed below. Most of these factors are suggested by their association with HF, although their causal relationships remain largely unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased circulating cytokines and the anemia of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation may contribute to the anemia seen in chronic heart failure. This view is supported by the finding of increased levels of circulating cytokines such as tumor necrosis factor-alpha and interleukin-6 in patients with HF, and increased levels of the acute phase reactants C-reactive protein, erythrocyte sedimentation rate, and serum ferritin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. Such changes are consistent with those found in patients with the anemia of chronic inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H4#H4\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'The role of cytokines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this mechanism is not supported by serum and urine levels of the iron regulatory peptide hepcidin in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Hepcidin levels are elevated in patients with overt anemia of inflammation, leading to decreased intestinal absorption of iron and sequestration of iron in the reticuloendothelial system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interestingly, although IL-6 levels were modestly elevated in patients with heart failure compared with levels in control subjects, hepcidin levels in those with heart failure were either decreased or similar to levels in control subjects. Taken together, the data suggest that the anemia of heart failure is not due to inflammation, or if inflammation is involved it is mediated through non-hepcidin dependent mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dilutional anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report of 37 patients with HF and anemia in whom the plasma volume was directly determined using iodine-131 labeled albumin, 17 had anemia on the basis of hemodilution (ie, an expanded plasma volume) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/21\">",
"     21",
"    </a>",
"    ]. The patients with hemodilution appeared to have a worse prognosis.",
"   </p>",
"   <p>",
"    In another study in 99 patients with heart failure, those with anemia had significantly increased plasma volume and no significant difference in red cell volume, as measured by a chromium-51 assay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency may be more common in HF patients than is suggested by iron studies alone, since the ferritin level may not correlate with low iron stores. This was illustrated in a series of 37 patients with advanced HF (mean left ventricular ejection fraction [LVEF] = 22 percent, mean NYHA class 3.7) and anemia. All patients underwent bone marrow aspiration. Based upon the absence of stainable iron in bone marrow aspirates in 27 of the patients, the prevalence of iron deficiency was 73 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum ferritin levels, however, were reduced in only two of the iron deficient patients, indicating that serum ferritin is not a reliable marker of iron deficiency in this population. Of note, the authors of the study do not report whether the required seven bone marrow particles were assessed in each patient to reliably establish the absence of stainable iron [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether these results reflect the prevalence of iron deficiency in populations with less severe HF is not known. In addition, the benefit of iron replacement was not assessed in this study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Use of angiotensin converting enzyme inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors, which prolong survival in patients with HF, also appear to induce anemia in selected patients. These drugs also reduce the hematocrit following renal transplantation, and have been used to treat erythrocytosis in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=see_link\">",
"     \"Erythrocytosis following renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of ACE inhibitors was evaluated in a report from the SOLVD trial in which patients with left ventricular dysfunction were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/24\">",
"     24",
"    </a>",
"    ]. At one year after randomization, the rate of new anemia (hematocrit &le;39 percent in men and &le;36 percent in women) was significantly higher in the enalapril group (11.3 versus 7.9 percent with placebo, adjusted odds ratio 1.56). The difference in hematocrit between the two groups was evident as early as six weeks.",
"   </p>",
"   <p>",
"    The effect of ACE inhibitors on hematocrit may be mediated by Ac-SDKP (goralatide), a tetrapeptide that inhibits erythropoiesis. Ac-SDKP is metabolized by angiotensin converting enzyme and would be expected to accumulate in the presence of an ACE inhibitor, thereby inhibiting erythropoiesis. This hypothesis was confirmed in a study of 10 anemic patients with advanced stable HF who were treated with an ACE inhibitor and had no other explanation for anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/25\">",
"     25",
"    </a>",
"    ]. These patients had a significant reduction in ACE activity and significantly higher levels of Ac-SDKP when compared with matched nonanemic controls who were also treated with an ACE inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal dysfunction and other contributing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When measured, mean serum creatinine levels have been elevated in a number of studies of anemic patients with HF, including those with cardiorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/6,9,10,16,26,27\">",
"     6,9,10,16,26,27",
"    </a>",
"    ]. Other contributing factors may include poor nutrition due to right-sided HF, decreased bone marrow perfusion, and the effects of drugs used to treat HF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/1,15\">",
"     1,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the increased age of many of these patients, the presence of myelodysplasia needs to be considered as a cause of the anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22538?source=see_link&amp;anchor=H13#H13\">",
"     \"Anemia in the older adult\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NORMAL HEMODYNAMIC RESPONSE TO ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, isovolemic reduction in the hemoglobin concentration produces a variety of compensatory hemodynamic changes that include a reduction in systemic vascular resistance and increases in heart rate, stroke volume, and cardiac index [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/28\">",
"     28",
"    </a>",
"    ]. These changes are combined with enhanced tissue oxygen extraction, which can increase from a baseline of 25 percent to a maximum of about 60 percent. The net effect is that oxygen delivery can be maintained at rest at a hemoglobin concentration below 5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (equivalent to a hematocrit of 15 percent), assuming that the intravascular volume is maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link&amp;anchor=H2#H2\">",
"     \"Indications for red cell transfusion in the adult\", section on 'Physiology of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hemodynamic effects of chronic anemia were evaluated in a study in which right heart catheterization was performed in anemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/29\">",
"     29",
"    </a>",
"    ]. Normal cardiac hemodynamics were maintained in patients with hemoglobin values as low as 7",
"    <span class=\"nowrap\">",
"     g/dL;",
"    </span>",
"    the cardiac output increased at lower hemoglobin concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Development of high-output HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe anemia is a rare cause of high-output heart failure. High output heart failure in the setting of anemia is more likely to occur in the setting of underlying cardiac abnormality such as valvular heart disease or left ventricular dysfunction. Only severe anemia, ie, hemoglobin less than 5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    can produce HF in the absence of underlying heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link&amp;anchor=H12#H12\">",
"     \"High-output heart failure\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic anemia may play a contributory role in the development of heart failure in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In one study of 432 such patients, each 1",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    decrease in hemoglobin was independently associated with left ventricular dilatation, the development of heart failure, and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IMPACT OF ANEMIA ON MORTALITY IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of retrospective studies have evaluated the relationship between anemia and mortality in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/1-3,7,13,24,32-41\">",
"     1-3,7,13,24,32-41",
"    </a>",
"    ]. Two studies found a J-shaped relationship between mortality and hemoglobin, with increased mortality associated with hemoglobin levels less than 13 to 14 or greater than 16 to 17",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Initial studies suggested that anemia independently predicts worse outcomes. However, in the largest observational study that controlled for the greatest number of possible confounding variables, anemia was not an independent predictor of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The independent prognostic significance of anemia in HF patients was suggested in a review of 1061 patients with NYHA class III or IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and an LVEF &lt;40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/13\">",
"     13",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower hemoglobin concentrations were associated with worse hemodynamics, higher blood urea nitrogen and serum creatinine concentrations, and a lower serum albumin concentration.",
"     </li>",
"     <li>",
"      Patients with lower hemoglobin concentrations (less than 13.6",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      had a significantly greater frequency of NYHA class IV HF and lower peak oxygen consumption.",
"     </li>",
"     <li>",
"      On multivariate analysis, a low hemoglobin concentration was an independent predictor of mortality (relative risk 1.13 for each 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      fall in hemoglobin concentration).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, in an analysis from the SOLVD trial, a low hemoglobin concentration was an independent predictor of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/2\">",
"     2",
"    </a>",
"    ]. At a mean follow-up of 33 months, each 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    reduction in hematocrit was associated with a significant 2.7 percent increase in mortality. These effects were seen in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or placebo. As noted above, the incidence of anemia was higher in the enalapril-treated group [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The time course of anemia appears to affect its prognostic significance. In a review of 6159 patients with chronic HF, anemia was present at baseline in 17.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/39\">",
"     39",
"    </a>",
"    ]. At six-month follow-up, persistent anemia was associated with higher mortality risk than no anemia (58 percent versus 31 percent), while transient anemia, which was present in almost one-half of anemic patients, conferred no excess mortality risk.",
"   </p>",
"   <p>",
"    These analyses, however, do not establish a causal role for anemia in worse outcomes in HF. Among the possible confounding variables is the possibility that advanced HF exacerbates anemia. If this were the case, anemia would be a marker for advanced disease. Two studies evaluated patients with new onset HF, in whom the anemia would be less likely to be due to the HF. Results from these observational studies were conflicting as to whether anemia is [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/3\">",
"     3",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/43\">",
"     43",
"    </a>",
"    ] an independent predictor of outcome. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a larger study, anemia was not an independent predictor of outcomes in over 50,000 HF patients &ge;65 years of age who were admitted to the hospital with a principal diagnosis of HF, either new or recurrent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/40\">",
"     40",
"    </a>",
"    ]. Although anemia was a significant predictor of one-year mortality, it was also associated with a wide range of possible confounding factors, including cardiac and noncardiac comorbidities, indices of HF severity, age, gender, and nursing-home residence. In multivariate analysis incorporating these variables, there was no difference in one-year mortality between patients with a normal hematocrit (40 to 44 percent) and those with severe anemia (hematocrit &le;24 percent). The authors suggested that prior studies were limited by exclusion criteria, small sample size and, most importantly, failure to incorporate the broad range of possible confounders.",
"   </p>",
"   <p>",
"    In summary, it remains uncertain whether anemia is an independent predictor of increased mortality or reflects more advanced disease and more extensive comorbidities. Prospective trials assessing the impact of treatments for anemia in HF patients will help to clarify this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Impact of endogenous erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low hemoglobin concentrations seen in patients with HF are associated with elevated plasma erythropoietin concentrations in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In one report of 108 patients with HF and 45 controls, plasma erythropoietin increased progressively with NYHA class (from 1.4",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    for NYHA class I to 34",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    for NYHA class IV).",
"   </p>",
"   <p>",
"    Elevated plasma erythropoietin has been correlated with a lower rate of survival. This was illustrated in a study of 74 patients with HF; approximately one-third each were NYHA class II, III, and IV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/46\">",
"     46",
"    </a>",
"    ]. Two-year mortality was significantly higher for patients with elevated (&ge;22.6",
"    <span class=\"nowrap\">",
"     mU/mL)",
"    </span>",
"    plasma erythropoietin (32 versus 16 percent). Both the hemoglobin concentration and plasma erythropoietin were independently predictive of survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Impact of changes in hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of changes in hemoglobin over time was evaluated in a retrospective analysis from the Val-HeFT trial. Independent of the presence or absence of anemia at baseline, changes in hemoglobin over a one-year period were inversely related to morbidity and mortality, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in the quartile with the largest average DECREASE in hemoglobin (14.2 to 12.6",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      had, when compared with the quartile with little change in hemoglobin (13.7 to 13.8",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      a significantly increased risk of morbid events and death (hazard ratio 1.4 and 1.6, respectively).",
"     </li>",
"     <li>",
"      On the other hand, increasing hemoglobin was associated with a significantly lower mortality rate in patients with and without anemia at baseline (hazard ratio 0.78 and 0.79, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations cannot distinguish between a direct effect of the hemoglobin concentration or the effect of systemic factors that affect both outcomes and the hemoglobin concentration in parallel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Impact of polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia, as well as anemia, is associated with increased mortality in patients with HF. This was illustrated in a study of 3044 patients participating in the ELITE II trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/47\">",
"     47",
"    </a>",
"    ]. The relationship between baseline hemoglobin concentration and survival was U-shaped, with the highest two-year survival rate (83 percent) among those with a hemoglobin of 14.0 to 15.0",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Patients in the subsets with lowest and highest hemoglobin (&lt;12.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and &gt;15.0",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively) both had lower two-year survival rates (75 and 78 percent, respectively).",
"   </p>",
"   <p>",
"    The reason for the association between a high hemoglobin concentration and mortality noted in this study is not clear. While the correlation persisted after correction for the diagnosis of COPD (in 9 percent of the subjects), no data were provided on the incidence of cigarette smoking or its correlation with hemoglobin concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20373056\">",
"    <span class=\"h2\">",
"     Impact of low transferrin saturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transferrin saturation (TSAT), which is normally in the range of 20 to 50 percent, can be reduced to &lt;20 percent in both iron deficiency and the anemia of inflammation. In one study of 157 patients with heart failure, TSAT was &lt;20 percent in 16, 72, and 100 percent of those with NYHA functional class I or II, III, and IV, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/48\">",
"     48",
"    </a>",
"    ]. A TSAT &lt;20 percent was associated with lower peak oxygen consumption and increased risk of morality at median two year follow-up (hazard ratio 3.4; 95% CI 1.5 to 7.7) and predicted mortality independent of hemoglobin.",
"   </p>",
"   <p>",
"    Thus, disordered iron homeostasis (ie, iron deficiency, anemia of inflammation, or both) in patients with heart failure is associated with both impaired exercise capacity and survival.",
"   </p>",
"   <p>",
"    Some have postulated that iron deficiency may directly affect myocardial function. A preliminary study found lower iron content and lower type 1 transferrin receptor mRNA levels in myocardial tissue from six explanted failing hearts compared to tissue from five unused donor hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/49\">",
"     49",
"    </a>",
"    ]. Further study is needed to determine whether there is relationship between myocardial iron deficiency and HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EFFECT OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations do not prove a cause-and-effect relationship between anemia and survival in patients with HF because anemia may simply be a reflection of more severe disease. Data on use of transfusions in this setting are lacking. The effects of treatment of anemia in HF patients with erythropoietic agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous iron have been assessed only in small trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Erythropoiesis stimulating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence does not support the use of erythropoiesis stimulating agents to treat anemia in patients with HF. The best evidence on the lack of efficacy and risk of complications of such treatment in this population comes from the Reduction of Events by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     Darbepoetin Alfa",
"    </a>",
"    in Heart Failure (RED-HF) trial which randomly assigned 2278 patients with systolic heart failure to treatment with either darbepoetin alfa (to achieve a hemoglobin target of 13",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/50\">",
"     50",
"    </a>",
"    ]. Darbepoetin alfa and placebo-treated groups had similar rates (50.7 and 49.6 percent) of the primary outcome of death from any cause or hospitalization for worsening heart failure at median 28 months follow-up. Rates of stroke were not significantly different in the two groups (3.7 and 2.7 percent) but thromboembolic adverse events were more frequent in the darbepoetin alfa-treated group (13.5 versus 10.0 percent).",
"   </p>",
"   <p>",
"    The finding of a significantly higher thromboembolic event rate along with a nonsignificantly higher stroke rate in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    group in the RED-HF trial is similar to the results of the TREAT trial, which compared darbepoetin alfa with placebo therapy in 4038 patients with diabetes, chronic kidney disease, and anemia (one-third with heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In the TREAT trial, the darbepoetin alfa-treated group had a significantly higher thromboembolic rate as well as significantly higher stroke rate compared to the placebo group. Possible mechanisms for an adverse effect of EPO therapy include worsening hypertension, increased risk of thrombotic events, and increased release of endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link&amp;anchor=H6#H6\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\", section on 'Randomized trials and systematic reviews'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, the 2278 subject double-blind RED-HF trial failed to confirm the suggestion of clinical benefit from erythropoiesis stimulating agents raised by an earlier meta-analysis of 11 small trials (five double-blind) with a total of 794 subjects with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/4,53-62\">",
"     4,53-62",
"    </a>",
"    ] and found an increased risk of thromboembolism with such treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intravenous iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized trials, one large [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/17\">",
"     17",
"    </a>",
"    ] and two small [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/18,63\">",
"     18,63",
"    </a>",
"    ] and a number of observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/6,10,26,64\">",
"     6,10,26,64",
"    </a>",
"    ] have provided evidence of symptomatic benefit from treating patients with chronic HF with intravenous iron with or without an erythropoiesis-stimulating agent. Iron deficiency as diagnosed by iron studies, was a criterion in the three randomized trials, although serum ferritin cut-off values were higher than those generally used in other populations to diagnose iron deficiency and none directly measured serum iron and total iron binding capacity. As a result, these studies probably included patients whose anemia was due, at least in part, to the anemia of chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H25#H25\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Diagnosis of ACD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The large trial (FAIR-HF trial) enrolled 459 patients with NYHA functional class II or III HF, left ventricular ejection fraction of &le;40 to 45 percent, iron deficiency, and a hemoglobin level of 9.5 to 13.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/17\">",
"     17",
"    </a>",
"    ]. For the purposes of this study, iron deficiency was defined as a serum ferritin level less than 100",
"    <span class=\"nowrap\">",
"     microg/L,",
"    </span>",
"    or between 100 and 299",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    with transferrin saturation less than 20 percent. Subjects were excluded if they had \"inflammation\", although this was not defined within the paper.",
"   </p>",
"   <p>",
"    The subjects were randomly assigned to receive intravenous iron (ferric carboxymaltose) or saline (placebo) at regular intervals during correction and maintenance phases. Those receiving intravenous iron demonstrated significantly higher self-reported Patient Global assessment, NYHA functional class, six-minute walk distance, and health-related quality of life at 24 weeks. These benefits were similar in patients with hemoglobin levels &le;12 or &gt;12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The rates of death and adverse events were similar in the two groups.",
"   </p>",
"   <p>",
"    These results are intriguing and raise several questions. The first is related to the underlying iron status of the study subjects. The mean ferritin levels were 52.5 and 60.1",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    in the ferric carboxymaltose and placebo groups, respectively. Thus, many subjects had ferritin levels well above a cutoff usually considered diagnostic of iron deficiency. Moreover, the combination of a ferritin &gt;100",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    and transferrin saturation &lt;20 percent is highly suggestive of the anemia of inflammation rather than iron deficiency, despite the exclusion of subjects with \"inflammation\".",
"   </p>",
"   <p>",
"    It is also of interest that the clinical benefit of intravenous iron was not dependent upon changes in the patients' hemoglobin levels, suggesting that alternate mechanisms led to the observed improvements. Finally, it is important to note the possibility of inadequate subject blinding to treatment group, due to differences in the color of the ferric carboxymaltose and placebo solutions, particularly in light of the relatively subjective outcome measures utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of anemia was not considered a routine therapy in HF patients in the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines, the 2006 Heart Failure Society of America guidelines, and the 2008 European Society of Cardiology (ESC) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. However, all of these guidelines were published before the large randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1705/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is frequently present in patients with heart failure (HF) and is often multifactorial. Multiple factors, including increased levels of circulating cytokines, hemodilution, iron deficiency, use of ACE inhibitors, renal insufficiency, and poor nutrition may be operative in an individual patient. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Effect on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anemia has been associated with higher mortality risk in patients with HF in several studies. However, it is uncertain whether anemia is an independent predictor of increased mortality or reflects more advanced disease and more extensive comorbidities. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Impact of anemia on mortality in HF'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its impact on the morbidity and mortality of HF, the various causes of anemia should be documented, and appropriately treated when possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H52#H52\">",
"     \"Approach to the adult patient with anemia\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22538?source=see_link&amp;anchor=H23#H23\">",
"     \"Anemia in the older adult\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suggested testing includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Iron studies (serum iron, transferrin, iron saturation, ferritin)",
"     </li>",
"     <li>",
"      Complete blood count, including red cell indices, reticulocyte count, and evaluation of the peripheral blood smear",
"     </li>",
"     <li>",
"      Serum levels of vitamin B12 and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"     </li>",
"     <li>",
"      Renal function (eg, creatinine, creatinine clearance)",
"     </li>",
"     <li>",
"      C-reactive protein and other inflammatory markers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with heart failure and chronic anemia, we suggest NOT routinely correcting the anemia by the use of transfusion or erythropoiesis stimulating agents. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Effect of treatment'",
"      </a>",
"      above.)&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Iron supplementation is recommended only when clinically indicated to treat documented iron deficiency anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"       \"Treatment of anemia due to iron deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      General indications for red cell transfusion apply to patients with heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"       \"Indications for red cell transfusion in the adult\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link&amp;anchor=H2#H2\">",
"       \"Use of blood products in the critically ill\", section on 'Red blood cells'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When red cell transfusion is required in a patient with HF, careful attention to volume status is recommended, including adjustment of transfusion rate and supplemental diuretics as needed to avoid volume overload. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"       \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While a single report suggests that intravenous iron provides symptomatic benefit in selected patients with HF, the long-term effects of such treatment are not known. Further studies are needed to investigate whether subjects with more stringently defined iron deficiency anemia (versus the anemia of inflammation) are more likely to benefit from intravenous iron, to investigate potential underlying mechanisms leading to benefit, and to confirm that there is no increased risk of adverse events over extended follow-up, before intravenous iron can be recommended as the standard of care in patients with HF.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/1\">",
"      Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/2\">",
"      Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/3\">",
"      Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/4\">",
"      Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/5\">",
"      Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/6\">",
"      Com&iacute;n-Colet J, Ruiz S, Cladellas M, et al. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail 2009; 15:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/7\">",
"      He SW, Wang LX. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail 2009; 15:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/8\">",
"      Mak G, Murphy NF, McDonald K. Anemia in heart failure: to treat or not to treat? Curr Treat Options Cardiovasc Med 2008; 10:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/9\">",
"      Silverberg DS, Wexler D, Iaina A, Schwartz D. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol 2009; 13:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/10\">",
"      Pagourelias ED, Koumaras C, Kakafika AI, et al. Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure? Angiology 2009; 60:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/11\">",
"      Silverberg DS, Wexler D, Palazzuoli A, et al. The anemia of heart failure. Acta Haematol 2009; 122:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/12\">",
"      Drakos SG, Anastasiou-Nana MI, Malliaras KG, Nanas JN. Anemia in chronic heart failure. Congest Heart Fail 2009; 15:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/13\">",
"      Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/14\">",
"      Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/15\">",
"      Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008; 52:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/16\">",
"      Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/17\">",
"      Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/18\">",
"      Toblli JE, Lombra&ntilde;a A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/19\">",
"      Matsumoto M, Tsujino T, Lee-Kawabata M, et al. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ J 2010; 74:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/20\">",
"      Divakaran V, Mehta S, Yao D, et al. Hepcidin in anemia of chronic heart failure. Am J Hematol 2011; 86:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/21\">",
"      Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/22\">",
"      Adlbrecht C, Kommata S, H&uuml;lsmann M, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008; 29:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/23\">",
"      Hughes DA, Stuart-Smith SE, Bain BJ. How should stainable iron in bone marrow films be assessed? J Clin Pathol 2004; 57:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/24\">",
"      Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005; 45:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/25\">",
"      van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005; 112:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/26\">",
"      Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/27\">",
"      Lu KJ, Kearney LG, Hare DL, et al. Cardiorenal Anemia Syndrome as a Prognosticator for Death in Heart Failure. Am J Cardiol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/28\">",
"      Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/29\">",
"      Brannon ES, Merrill AJ, Warren JV, Stead EA. THE CARDIAC OUTPUT IN PATIENTS WITH CHRONIC ANEMIA AS MEASURED BY THE TECHNIQUE OF RIGHT ATRIAL CATHETERIZATION. J Clin Invest 1945; 24:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/30\">",
"      Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/31\">",
"      Silberberg JS, Rahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 1989; 64:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/32\">",
"      Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/33\">",
"      Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/34\">",
"      Kosiborod M, Smith GL, Radford MJ, et al. The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/35\">",
"      Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/36\">",
"      Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/37\">",
"      Maggioni AP, Opasich C, Anand I, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 2005; 11:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/38\">",
"      Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006; 27:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/39\">",
"      Tang WH, Tong W, Jain A, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008; 51:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/40\">",
"      Kosiborod M, Curtis JP, Wang Y, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 2005; 165:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/41\">",
"      Dunlay SM, Weston SA, Redfield MM, et al. Anemia and heart failure: a community study. Am J Med 2008; 121:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/42\">",
"      Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/43\">",
"      Kalra PR, Collier T, Cowie MR, et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 2003; 362:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/44\">",
"      Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994; 74:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/45\">",
"      Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail 2000; 2:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/46\">",
"      van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/47\">",
"      Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/48\">",
"      Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011; 58:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/49\">",
"      Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 2011; 58:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/50\">",
"      Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/51\">",
"      Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/52\">",
"      Marsden PA. Treatment of anemia in chronic kidney disease--strategies based on evidence. N Engl J Med 2009; 361:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/53\">",
"      Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/54\">",
"      Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/55\">",
"      Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/56\">",
"      Palazzuoli A, Silverberg DS, Iovine F, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154:645.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/57\">",
"      Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/58\">",
"      Ngo K, Kotecha D, Walters JA, et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010; :CD007613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/59\">",
"      Jin B, Luo X, Lin H, et al. A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure. Eur J Heart Fail 2010; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/60\">",
"      Timmer SA, De Boer K, Knaapen P, et al. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail 2009; 15:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/61\">",
"      Parissis JT, Kourea K, Andreadou I, et al. Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2009; 103:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/62\">",
"      Kotecha D, Ngo K, Walters JA, et al. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 2011; 161:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/63\">",
"      Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/64\">",
"      Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/65\">",
"      Dec GW. Anemia and iron deficiency--new therapeutic targets in heart failure? N Engl J Med 2009; 361:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/66\">",
"      Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/67\">",
"      . Nonpharmacologic management and health care maintenance in patients with chronic heart failure. J Card Fail 2006; 12:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1705/abstract/68\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3483 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1705=[""].join("\n");
var outline_f1_42_1705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased circulating cytokines and the anemia of inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dilutional anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Use of angiotensin converting enzyme inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal dysfunction and other contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NORMAL HEMODYNAMIC RESPONSE TO ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Development of high-output HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IMPACT OF ANEMIA ON MORTALITY IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Impact of endogenous erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Impact of changes in hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Impact of polycythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20373056\">",
"      Impact of low transferrin saturation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EFFECT OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Erythropoiesis stimulating agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intravenous iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Effect on survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3483|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22538?source=related_link\">",
"      Anemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=related_link\">",
"      Erythrocytosis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_42_1706="Exercise-associated hyponatremia";
var content_f1_42_1706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise-associated hyponatremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1706/contributors\">",
"     Mitchell H Rosner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1706/contributors\">",
"     Tamara Hew-Butler, DPM, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1706/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1706/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/42/1706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/42/1706/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/42/1706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe and potentially life-threatening hyponatremia can occur during exercise, particularly in athletes participating in endurance events such as marathons (42.2 km), triathlons (3.8 km swim, 180 km cycling, and 42.2 km running), and ultradistance (100 km) races [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. A similar problem can occur during military operations and desert hikes.",
"   </p>",
"   <p>",
"    Exercise-associated hyponatremia (EAH) was first described in Durban, South Africa in 1981 and in 1985 in four athletes participating in endurance events longer than seven hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/5\">",
"     5",
"    </a>",
"    ]. Prior to 1981, athletes were advised to avoid drinking during exercise, leading to the development of hypernatremia in some athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Subsequently, athletes were advised to consume as much fluid as possible during exercise. Concomitant with these recommendations, the incidence of hyponatremia in endurance athletes appeared to increase, particularly in the United States.",
"   </p>",
"   <p>",
"    The majority of athletes who develop hyponatremia are asymptomatic or mildly symptomatic (eg, weakness, dizziness, headache, lethargy,",
"    <span class=\"nowrap\">",
"     nausea/vomiting).",
"    </span>",
"    However, severe manifestations can occur, including seizures, cerebral edema, noncardiogenic pulmonary edema, and death. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Clinical manifestations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 Second International Exercise-Associated Hyponatremia Consensus Development Conference defined EAH as hyponatremia (serum or plasma sodium below the normal reference range of the laboratory) occurring during or up to 24 hours after prolonged physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the recognition that drinking large volumes of water can lead to potentially fatal hyponatremia, it was not rare for endurance athletes to be hyponatremic at the end of the race, usually in the absence of overt central nervous system symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,2,9-17\">",
"     1,2,9-17",
"    </a>",
"    ]. The incidence of hyponatremia has varied, ranging from 0 to 18 percent in marathoners and triathletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2,10,14-16\">",
"     2,10,14-16",
"    </a>",
"    ] to 51 percent of runners participating in a 161 km mountain footrace, which suggests that EAH may be more prevalent in extreme endurance events lasting more than 24 h [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study at the 2002 Boston Marathon (26.2 miles, 42.2 km), a sample of 766 runners approached randomly at race registration completed a survey prior to the race and, at the finish line, provided a blood sample and completed a questionnaire detailing their fluid consumption and urine output during the race [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"       1",
"      </a>",
"      ]. Among these runners, 511 reported to the finish line station and an adequate blood sample was obtained from 488. Of these, 13 percent had hyponatremia (defined as a serum sodium concentration &le;135",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and three runners (0.6 percent) had what was considered critical hyponatremia (serum sodium concentration &le;120",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"       1",
"      </a>",
"      ]. If this sample was representative of the almost 15,000 runners who finished the race, then 1900 of all finishers would have some degree of hyponatremia and 90 would have critical hyponatremia.",
"     </li>",
"     <li>",
"      The largest experience comes from a review of 2135 athletes in reported endurance events in which both serum sodium and body weight changes after racing were available: 6 percent had a serum sodium between 129 and 135",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and 1 percent had a serum sodium below 129",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, 13 percent were hypernatremic (serum sodium greater than 145",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      due to inadequate fluid intake during the race. Hypernatremia has also been noted in other series [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of hyponatremia may be higher in runners of ultramarathons [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. As an example, 30 percent of runners completing a 161 km mountain race were found to have asymptomatic mild hyponatremia, associated with a loss of body weight in half of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon such observations, the recommendations for fluid intake during an endurance event were changed to drinking according to thirst. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors have been linked with the development of EAH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,2,8,13\">",
"     1,2,8,13",
"    </a>",
"    ]. The most important is high fluid intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factor for EAH appears to be a high rate of fluid consumption during and after exercise, leading to water overload and hemodilution [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,2,8,9,12,16,21,22\">",
"     1,2,8,9,12,16,21,22",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the report from the Boston Marathon, hyponatremia was independently associated with weight gain during the marathon; 44 of 62 runners who developed hyponatremia gained weight during the race compared with 124 of 426 runners who did not develop hyponatremia (71 versus 29 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"       1",
"      </a>",
"      ]. This corresponded to the frequency and volume of fluid intake, which was significantly higher in the athletes who developed hyponatremia. Furthermore, the severity of hyponatremia was associated with the amount of weight gained. Of the runners who gained at least 2.0 kg, 17 percent developed severe hyponatremia (defined as a serum sodium less than or equal to 130",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      compared with 3 percent in runners who gained between 0.0 and 1.9 kg.",
"     </li>",
"     <li>",
"      Similar findings were noted in the review of 2135 athletes in endurance events [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"       2",
"      </a>",
"      ]. The mean serum sodium was 136",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the athletes who gained weight during the race compared with 141",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the athletes who either maintained weight or lost weight. Of the athletes who gained weight, 19 percent had a serum sodium between 129 and 135",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and 11 percent had a serum sodium below 129",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      The comparable values in athletes who did not gain weight were 4 and 0.3 percent, respectively.",
"      <br/>",
"      <br/>",
"      The authors estimated that athletes who gained more than 4 percent body weight during exercise had an 85 percent probability of developing hyponatremia and a 45 percent probability of developing hyponatremic encephalopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most athletes who develop EAH, the excessive fluid intake reflects conditioned behavior based upon recommendations to drink fluid during exercise to avoid dehydration. In a study from the 1998 and 1999 Suzuki Rock 'N' Roll Marathons, for example, the 26 runners who developed hyponatremia reported \"drinking as much as possible\" during and after the race [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, there were no cases of hyponatremia among 134 runners who finished the in the 2002 City of Christchurch marathon, [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/15\">",
"     15",
"    </a>",
"    ]. In this race, aggressive hydration was not promoted and there were fewer hydration stations than there were in the 2002 Boston Marathon (every 5 versus 1.6 km) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The consumption of a",
"    <span class=\"nowrap\">",
"     carbohydrate/electrolyte",
"    </span>",
"    containing sports drink does",
"    <strong>",
"     not",
"    </strong>",
"    provide protection against the development of hyponatremia since most of these drinks are markedly hypotonic to plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,8,23\">",
"     1,8,23",
"    </a>",
"    ]. Gatorade&reg;, for example, has a sodium plus potassium concentration of only 23",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (potassium is as osmotically active as sodium) compared with approximately 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in normal plasma. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other independent risk factors for EAH in different series included longer race time (or the related variable of slower training pace), and a low body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,8,9,12\">",
"     1,8,9,12",
"    </a>",
"    ]. As an example, the following observations were made in the report from the Boston Marathon [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"     1",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-two percent of runners who developed hyponatremia had race times above four hours compared with 13 percent in those who finished the race in less than 3.5 hours. Longer race times probably correlate with increased water consumption and increased sodium losses.",
"     </li>",
"     <li>",
"      Thirty-two percent of runners who developed hyponatremia had a body mass index less than 20",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      compared with 14 percent in runners whose body mass index was greater or equal to 25",
"      <span class=\"nowrap\">",
"       kg/m2.",
"      </span>",
"      A possible mechanism is that ingestion of a given volume of water would lead to a greater reduction in serum sodium in individuals with a low body mass index, since their total body water is lower at baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs (NSAIDs) are used by as many as 50 to 60 percent of marathon runners. Some studies have found an association between NSAID use and the development of hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,9,14,24,25\">",
"     8,9,14,24,25",
"    </a>",
"    ], although NSAID use was not an independent risk factor in the 2002 Boston Marathon study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSAIDs increase the activity of antidiuretic hormone (ADH, also called arginine vasopressin) by removing the inhibitory effect of prostaglandins. The ensuing decrease in water excretion, which has been demonstrated in athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/25\">",
"     25",
"    </a>",
"    ], could promote the development of hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs: Electrolyte complications\", section on 'Hyponatremia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Sweat sodium loss'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Longer races may be associated with an increased risk of hyponatremia independent of other factors. In a study of 47 runners completing a 161 km mountain race, 30 percent had a serum sodium less than 135",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/19\">",
"     19",
"    </a>",
"    ]. A gain in weight, longer race time, and user of NSAIDs did not predict the development of hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased fluid intake is necessary but is not the sole explanation for many if not most cases of EAH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. The other major factor is impaired urinary water excretion due to persistent secretion of antidiuretic hormone (ADH, also called arginine vasopressin). Other proposed mechanisms of hyponatremia include a failure to mobilize exchangeable sodium stores and sodium losses in sweat [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264938073\">",
"    <span class=\"h2\">",
"     Increased fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, increased fluid intake appears to be the primary risk factor for exercise-associated hyponatremia (EAH). Another source of water is the breakdown of glycogen during exercise, since glycogen associates with \"bound\" water [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This release of water would not lead to weight gain.",
"   </p>",
"   <p>",
"    Despite the water load, individuals on a regular diet who have normal renal function have a maximum water excretory capacity that, depending upon diet, can exceed 500 to 1000",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. When one adds sweat and insensible fluid losses, which may be as high as 500",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ], athletes should be able to consume as much as 1000 to 1500",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    before retaining fluid and becoming hyponatremic. Based upon these calculations, it has been suggested that endurance athletes should not drink more than 1500",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    of fluid during a race [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the high rate of water loss, water loading alone is not likely to produce more than a modest reduction in serum sodium in most endurance athletes. This was shown in the review of 2135 endurance athletes cited above: only 30 percent of athletes who gained weight during the race developed hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Persistent secretion of ADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia due to water loading alone should suppress the release of ADH (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 1",
"    </a>",
"    ), leading to a maximally dilute urine with a urine osmolality as low as 30 to 50",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in healthy individuals and a urine output that can exceed 500 to 1000",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. Failure to suppress ADH release can markedly reduce water excretory capacity. As an example, low level persistence of ADH that results in a urine osmolality of 150",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    which is still hypotonic to plasma, diminishes the rate of water excretion by two-thirds compared with a urine osmolality of 50",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    This is particularly important when there is a marked increase in water intake [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link&amp;anchor=H8#H8\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\", section on 'Osmoreceptors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available data suggest that many patients with EAH have submaximal suppression of ADH secretion, an inappropriately high urine osmolality, and fulfill the criteria for the syndrome of inappropriate ADH secretion (SIADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,21,22,30-34\">",
"     8,21,22,30-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of the patient with hyponatremia\", section on 'Findings in SIADH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These features were illustrated in a review of hyponatremia in marathon runners [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22\">",
"     22",
"    </a>",
"    ]. Among 16 athletes with EAH after the 2004 Boston Marathon, seven had persistent secretion of ADH. In two runners with severe EAH at other marathons who collapsed and were unresponsive, the urine osmolality was inappropriately high (329 and 121",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    and the urine sodium concentration was 81 and 25",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    findings that are consistent with SIADH.",
"   </p>",
"   <p>",
"    There are a number of nonosmotic mechanisms by which ADH secretion might be inappropriately stimulated in endurance athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/21,32\">",
"     21,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intense exercise itself [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nonspecific stresses such as pain and emotion [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The release of muscle-derived interleukin-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to inappropriate ADH release, endurance athletes may develop what has been called appropriate ADH release due, for example, to hypovolemia resulting from sodium loss in sweat (",
"    <a class=\"graphic graphic_figure graphicRef58012 \" href=\"UTD.htm?2/33/2589\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Sweat sodium loss'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link&amp;anchor=H10#H10\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\", section on 'Volume receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most comprehensive study of ADH metabolism in endurance athletes evaluated 82 ultramarathon (35 miles, 56 km) runners who ran for a mean of six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/32\">",
"     32",
"    </a>",
"    ]. With ad libitum fluid intake, the plasma sodium was maintained (139.3 versus 138.1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline and the end of the race, respectively). Plasma ADH was elevated 3.9-fold at the end of the race, which could be explained at least in part by a mean 3.8 kg weight loss and an 8.5 percent reduction in plasma volume. There was also increased release of other hormones such as oxytocin and, despite the fall in plasma volume, N-terminal pro-brain natriuretic peptide. Whether these hormonal changes contributed to ADH release could not be determined. A similar study performed in 33 endurance cyclists participating in a 109 km race also documented nonosmotic ADH secretion after roughly five hours of cycling [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The applicability of these findings to EAH is uncertain since, as noted above, EAH primarily occurs in endurance athletes who gain weight during the event and would therefore be unlikely to have a hypovolemic stimulus to ADH release [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The exact nonosmotic stimulus to ADH secretion is unclear, but these field investigations suggest that the potential for nonosmotic ADH stimuli during competitive long-distance exercise is higher than previously noted in well-controlled laboratory settings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Overall, hyponatremia, particularly severe hyponatremia, is rare in athletes who lose weight during the event [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'High fluid intake'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of exchangeable sodium stores",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the review of 2135 endurance athletes cited above, 70 percent of athletes who gained weight maintained normal serum sodium concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ]. In some cases, the amount of fluid retained was too small to reduce the serum sodium below 135",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    It is also possible that, when the serum sodium was measured at the end of the race, some ingested water had not yet been absorbed from the gastrointestinal tract, contributing to weight gain without lowering the serum sodium concentration.",
"   </p>",
"   <p>",
"    A third possible mechanism for maintenance of normonatremia despite the weight gain is the release of sodium from internal stores [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ]. Up to 25 percent of body sodium is bound in bone and, although not osmotically active, is potentially recruitable into an osmotically active form [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In theory, this pool could minimize the fall in serum sodium induced by overhydration.",
"   </p>",
"   <p>",
"    The issue of recruiting osmotically active sodium from internal, not osmotically active sources, was addressed in a review of 18 athletes who were hospitalized for encephalopathy due to EAH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ]. Sodium and water balance was estimated at the time of admission and measured during recovery in the hospital. At the time of admission, the predicted serum sodium based upon electrolyte and water balance estimates was higher than the actual measured concentration in 14 athletes, suggesting exchange of sodium from an osmotically active to inactive state, and worsening of rather than protection against hyponatremia. During recovery, eight of the athletes showed evidence of osmotic activation of sodium (ie, the increase in serum sodium was more than could be explained by measured values of sodium and water balance), while 10 showed evidence of osmotic inactivation of sodium (ie, the increase in serum sodium was less than could be explained by measured values of sodium and water balance).",
"   </p>",
"   <p>",
"    These disparate findings are difficult to explain physiologically, and the following factors could contribute to the observed findings without invoking osmotic activation or inactivation of internally exchangeable sodium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absorption of ingested water still in the gastrointestinal tract would lower the serum sodium without a change in weight, falsely suggesting osmotic inactivation. There is some evidence of delayed gastric emptying during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The breakdown of glycogen into smaller, more osmotically active molecules (such as lactate) during exercise can increase the cell osmolality, thereby causing the osmotic movement of water into the cells and raising the serum sodium [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/46\">",
"       46",
"      </a>",
"      ]. This effect reverses within five minutes after the cessation of exertion [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes in potassium balance, which were not measured, could have influenced the serum sodium concentration without affecting body weight. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Effect of potassium'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sweat sodium loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a variable degree of sodium loss from sweating. The concentration of sodium in sweat ranges from 15 to 65",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Compared with the general population, fit athletes generally have a lower sweat sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], a higher rate of sweat production in proportion to the degree of fitness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and an earlier onset of sweating [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/51\">",
"     51",
"    </a>",
"    ]. The sweat rate during exercise is primarily determined by the increase in metabolic rate; thus, for athletes of the same body weight, the sweat rate will be higher in those who run faster. In contrast, nonfit athletes, who are at greatest risk of EAH, tend to be heavier and may have a similar rate of sweat loss even though they run more slowly than the thinner fit athletes.",
"   </p>",
"   <p>",
"    The direct effect of losing hypotonic sweat would be to raise the serum sodium. However, sweat loss could contribute to the development of hyponatremia if the degree of fluid loss were sufficient to produce significant volume depletion, providing a hypovolemic stimulus to ADH release, which, as described above, would impair excretion of ingested water.",
"   </p>",
"   <p>",
"    The contribution of sweat-induced hypovolemia sufficient to increase ADH release is probably small in endurance athletes based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the review of 2135 endurance athletes cited above, only 3.5 percent of those athletes who lost more than 3 kg during the race (which would have been due in part to sweating) had a serum sodium between 129 and 135",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at the end of the race and no athlete had a serum sodium below 129",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"       2",
"      </a>",
"      ]. The rates were much higher (19 and 11 percent) in the athletes who gained weight during the race. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'High fluid intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The total body sodium deficit is relatively small in athletes with EAH [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2,52,53\">",
"       2,52,53",
"      </a>",
"      ]. Among 18 athletes hospitalized for hyponatremic encephalopathy, the mean sodium deficit was 104 meq, which was not significantly different from that in a control group of runners who did not develop hyponatremia (mean 187 meq) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"       2",
"      </a>",
"      ]. This observation is consistent with another report in which the plasma volume was maintained in 181 triathletes despite a mean weight loss of 4.9 kg during the race [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of acute hyponatremia due to exercise-associated hyponatremia (EAH) vary with severity and are at least in part related to cerebral edema resulting from osmotic water movement from the extracellular fluid into the brain. Severe manifestations of EAH include seizures, confusion, coma, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,9,22,24,29\">",
"     8,9,22,24,29",
"    </a>",
"    ]. Cerebral edema can often be demonstrated on CT scan or at postmortem examination. Although the mechanism is uncertain, noncardiogenic pulmonary edema has also been described in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/24,55\">",
"     24,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H3#H3\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Clinical manifestations of acute hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264939620\">",
"    <span class=\"h2\">",
"     Relation to serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of hyponatremic athletes are asymptomatic or mildly symptomatic, with nonspecific manifestations such as weakness, dizziness, bloating, headache, nausea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,2,8,9,22,29\">",
"     1,2,8,9,22,29",
"    </a>",
"    ]. These athletes usually have serum sodium values ranging from 128 to 134",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Headache and vomiting, especially when accompanied by lethargy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    confusion, should be considered warning signs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the likelihood and severity of symptoms attributable to hyponatremia increase with more severe disease, the effect is not predictable, as illustrated in the review of 2135 endurance athletes cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ]. Among 24 runners with central nervous system symptoms compatible with hyponatremic encephalopathy, 4 had a serum sodium &ge;130",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    with the highest value being 132",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    On the other hand, 4 of 15 runners with a serum sodium &le;125",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    were considered asymptomatic.",
"   </p>",
"   <p>",
"    Some hyponatremic athletes complain only of feeling ill, lie quietly in a corner, often in a fetal position, and want to avoid light and contact with other people. They appear lucid, but cannot concentrate and may be a little confused. The serum sodium is reduced but is often above 130",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Such patients typically respond dramatically to hypertonic saline, but therapy may be delayed because the role of hyponatremia is not recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     The collapsed athlete",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common scenario for medical personnel staffing endurance athletic events is the care of the \"collapsed athlete.\" Only a minority of these athletes have hyponatremia and a greater proportion have hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/18,22,29,57\">",
"     18,22,29,57",
"    </a>",
"    ]. The largest reported experience includes 1319 collapsed runners at the Boston Marathon between 2001 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/57\">",
"     57",
"    </a>",
"    ]. Hyponatremia was present in 5 percent and hypernatremia in 28 percent. Thus, collapsed athletes should",
"    <strong>",
"     not",
"    </strong>",
"    be treated for hyponatremia until the diagnosis is confirmed.",
"   </p>",
"   <p>",
"    The rate of hyponatremia would be higher when athletes were advised to consume as much fluid as possible during exercise. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955987\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis in association with EAH has been described in occasional ultramarathon runners participating in races greater than 153 km (96 miles) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. It was suggested in these reports that hyponatremia might increase the susceptibility for muscle cell damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any endurance athlete presenting with signs or symptoms compatible with hyponatremia should be screened by direct measurement of the serum or plasma sodium. The 2007 Second International Exercise-Associated Hyponatremia Consensus Development Conference recommended that medical facilities at endurance events should have onsite capability for such measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At endurance events in which the serum or plasma sodium cannot be measured, a presumptive diagnosis of EAH is sometimes made in the athlete with severe CNS manifestations (eg, seizures and coma) consistent with hyponatremic encephalopathy in whom there is no other obvious cause. As noted below, empiric therapy with hypertonic saline may be initiated in such patients. In comparison, the presence of EAH should",
"    <strong>",
"     not",
"    </strong>",
"    be assumed in collapsed athletes without measurement of the serum or plasma sodium, since hyponatremia is present in only a small proportion of these individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'The collapsed athlete'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, medical facilities at endurance events should be able to measure the serum or plasma sodium concentration in any athlete manifesting symptoms compatible with EAH, particularly those with severe symptoms suggesting hyponatremic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective controlled trials that have evaluated the efficacy and safety of different therapeutic regimens in patients with EAH. Treatment recommendations are based upon the limited data from small, uncontrolled case series, our current understanding of the pathogenesis of hyponatremia, and the treatment of hyponatremia in other settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most athletes with mild hyponatremia (serum sodium 130 to 135",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    are asymptomatic and will not be identified unless laboratory testing is performed for some other reason. If hyponatremia is identified, the recommended approach is restriction of fluid intake until the onset of a spontaneous diuresis; in addition, such athletes should be advised to seek urgent medical attention if signs or symptoms compatible with hyponatremia develop [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach to the treatment of symptomatic EAH is consistent with the recommendations made by the 2007 Second International Exercise-Associated Hyponatremia Consensus Development Conference [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ]. Administration of hypotonic or isotonic fluids should be avoided in all hyponatremic patients, since this regimen can exacerbate the hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mild to moderate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endurance athletes with mild to moderate symptoms (eg, headache, dizziness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nausea and vomiting) and",
"    <strong>",
"     documented",
"    </strong>",
"    hyponatremia should be treated at a minimum, with fluid restriction, and should be observed until the onset of a spontaneous diuresis, which will correct the hyponatremia and lead to resolution of the symptoms. An intravenous bolus of hypertonic saline is without harm and has potential benefit, particularly if symptoms seem to be progressing. However, we would",
"    <strong>",
"     not",
"    </strong>",
"    give hypertonic saline if the plasma or serum sodium cannot be measured, since similar symptoms can occur with hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/18\">",
"     18",
"    </a>",
"    ], which would be exacerbated by hypertonic saline, and, as noted above, hypernatremia is more common than hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Use of hypertonic saline'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A possible alternative in patients with suspected EAH if intravenous hypertonic saline is unavailable is oral therapy with a hypertonic broth (120 mL oral bolus of 9 percent saline). Among 3 marathoners in one report who fulfilled these criteria, the clinical manifestations improved in every patient without the need for intravenous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/57\">",
"     57",
"    </a>",
"    ]. However, there are insufficient data about the safety and efficacy of this therapy to support its use if hypertonic saline can be administered.",
"   </p>",
"   <p>",
"    Intravenous isotonic saline should",
"    <strong>",
"     not",
"    </strong>",
"    be used since it may worsen the hyponatremia if the patient is euvolemic and has elevated ADH levels with a urine osmolality above 300",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    Why this occurs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Intravenous saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary indication for isotonic saline is in the infrequent athlete with mild hyponatremia who has signs of volume depletion. As noted above, hyponatremia is less common in patients who lose weight during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ] and the total body sodium deficit is usually relatively small in athletes with EAH. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Sweat sodium loss'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes with hyponatremia and severe symptoms (eg, seizures, confusion, coma) should be treated with hypertonic (usually 3 percent) saline [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,9,22,24,29,60\">",
"     8,9,22,24,29,60",
"    </a>",
"    ]. In the largest series, encephalopathy was only seen when the serum sodium was &le;132",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22\">",
"     22",
"    </a>",
"    ]. However, EAH with encephalopathy has rarely been described at somewhat higher serum sodium concentrations (eg, 134",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in an Ironman triathlete) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the significant risk of delayed therapy in such patients, we recommend treatment in the field by experienced medical personnel with immediate transport to the hospital. If the serum or plasma sodium cannot be measured on site, it is reasonable to empirically initiate hypertonic saline (as described in the next section) if there is no other obvious cause for the neurologic manifestations. A small elevation in serum sodium can lead to significant symptomatic improvement and should produce no harm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22,56,61\">",
"     22,56,61",
"    </a>",
"    ]. Furthermore, delaying therapy can lead to worsening of the hyponatremia and possible clinical deterioration due to ongoing absorption of water from the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Use of hypertonic saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of hypertonic saline in severe symptomatic EAH was illustrated in a series of seven previously healthy marathon runners who collapsed after competing in a marathon and had nausea, vomiting, obtundation, cerebral edema (usually detected on computed tomography), noncardiogenic pulmonary edema, and a mean serum sodium of 121",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (range 117 to 127",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/24\">",
"     24",
"    </a>",
"    ]. Six were treated with hypertonic (3 percent) saline; all recovered and were well at 3 to 24 month follow-up. One patient died; this patient was not suspected of having hyponatremia, and therefore was not treated with hypertonic saline. An important observation in this report is that noncardiogenic pulmonary edema is",
"    <strong>",
"     not",
"    </strong>",
"    a contraindication to hypertonic saline administration in patients with hyponatremic encephalopathy.",
"   </p>",
"   <p>",
"    The 2007 Second International Exercise-Associated Hyponatremia Consensus Development Conference and others recommend that athletes with hyponatremic encephalopathy (eg, seizures, confusion, coma) and athletes with compatible symptoms (if the plasma or serum sodium cannot be measured) be immediately treated with a 100 mL bolus of 3 percent saline [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,60,62\">",
"     8,60,62",
"    </a>",
"    ]. This regimen should acutely raise the serum sodium concentration by 2 to 3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    thereby reducing the degree of cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/56\">",
"     56",
"    </a>",
"    ]. There is clear potential benefit from this approach with no proven harm, since the sodium load is only 51 meq.",
"   </p>",
"   <p>",
"    If neurologic symptoms persist or worsen prior to arrival at the hospital, the Consensus Development Conference recommends that a 100 mL bolus of 3 percent saline can be given one or two more times at ten minute intervals",
"    <strong>",
"     only",
"    </strong>",
"    if the plasma or serum sodium has been measured to confirm the presence of hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All such patients should be transported to a medical center where the serum sodium and neurologic status can be closely monitored; care should be taken to avoid delays in treatment of the hyponatremia while awaiting results of diagnostic imaging tests [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertonic saline should be discontinued as soon as the neurologic symptoms resolve, which typically occurs when the serum sodium has risen 3 to 7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    above the initial value [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22,61\">",
"     22,61",
"    </a>",
"    ]. Correction of the remaining hyponatremia will occur spontaneously from a water diuresis once ADH secretion wears off [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Persistent secretion of ADH'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A potential diagnostic problem in patients who have had seizures is that persistent neurologic symptoms may reflect a postictal state rather than persistent hyponatremic encephalopathy. Specific data are limited, but two points deserve emphasis: hyponatremia as the cause of ongoing symptoms is probably unlikely if the serum sodium has risen by 7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more above the initial value [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22,61\">",
"     22,61",
"    </a>",
"    ]; and a postictal state probably does not explain symptoms lasting more than 30 to 60 minutes after a single seizure in otherwise healthy individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rate of correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A final therapeutic issue is the clinical importance, if any, of the rate of correction of EAH. Among patients with chronic hyponatremia, overly rapid correction (a rise in serum sodium of 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more in the first 24 hours) can lead to severe and irreversible neurologic complications due to osmotic demyelination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of correction should be much less important in EAH, which is a very acute event that does not generate the cerebral adaptations that account for the risk of overly rapid correction in chronic hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmolytes and cerebral adaptation to hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no reported cases of osmotic demyelination in EAH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,22,29\">",
"     8,22,29",
"    </a>",
"    ], and anecdotal episodes of rapid correction of the hyponatremia have been well tolerated. In a series of six patients with hyponatremic encephalopathy who were treated with hypertonic saline, the serum sodium increased by 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in less than 12 hours, a rate of correction greater than recommended for chronic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/24\">",
"     24",
"    </a>",
"    ]. In another reported case of EAH with encephalopathy, hypertonic saline therapy was associated with a 13",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    elevation in the serum sodium in 8.5 hours without the development of osmotic demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/22\">",
"     22",
"    </a>",
"    ]. In all of these athletes, the central nervous system symptoms from EAH resolved, and there were no residua at 3 to 24 month follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to hyponatremia due to water overload, endurance athletes can become hypernatremic if they do not drink a sufficient quantity of water during the race. The reported incidence of hypernatremia (serum sodium &gt;145",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    was 13 percent in a review of 2135 endurance athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"     2",
"    </a>",
"    ] and 28 percent in a series of 1319 collapsed marathon runners [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment consists of the administration of hypotonic fluid to lower the serum sodium. Since hypernatremia stimulates thirst, such athletes can replace the water deficit by drinking. Intravenous therapy is required in athletes who cannot take oral fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link\">",
"     \"Treatment of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since consumption of fluid in excess of urinary and sweat losses is the primary mechanism of exercise-associated hyponatremia, most efforts at prevention of EAH have focused on education about the risks of the overconsumption of fluids. Given the wide variation in sweat production and renal water excretory capacity both between individual athletes and in the same individual depending upon ambient conditions during the race, universal guidelines for prevention are not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most settings, the regulatory system surrounding the maintenance of plasma sodium is so efficient that the plasma osmolality is maintained within a range of 1 to 2 percent despite wide variations in sodium and water intake. This depends upon an intact thirst mechanism and appropriate regulation of ADH release. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H96014928#H96014928\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Regulation of water and sodium balance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, some suggested that fluid intake be limited to 400 to 800",
"    <span class=\"nowrap\">",
"     mL/h.",
"    </span>",
"    However, sweat rates may not be this high, particularly in endurance athletes exercising in the cold. Thus, the risk of EAH would still be present.",
"   </p>",
"   <p>",
"    We agree with the recommendations from the 2007 Second International Exercise-Associated Hyponatremia Consensus Development Conference, which concluded that endurance athletes should",
"    <strong>",
"     drink according to thirst",
"    </strong>",
"    during the race [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ]. A prospective study in eight female marathon runners found that such an approach replaced most of the sweat losses with no evidence of overhydration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One method that has been used in an attempt to limit excessive water intake is to have fewer water stations. In the 2002 City of Christchurch marathon, aggressive hydration was not promoted and there were fewer hydration stations (every 5 versus 1.6 km) than in the 2002 Boston Marathon [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/15\">",
"     15",
"    </a>",
"    ]. There were no cases of hyponatremia among 134 runners who finished the race compared to an incidence of 13 percent in the Boston Marathon [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"     1",
"    </a>",
"    ]. For Ironman distance triathlons, hydration stations every 2.5 km when running and every 20 km when cycling have been recommended in addition to education about fluid intake [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,64\">",
"     8,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two additional recommendations have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onsite analysis of serum or plasma sodium should be available in medical facilities at endurance events [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of the USA Track and Field (USATF) guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/65\">",
"       65",
"      </a>",
"      ], or other methods, to estimate hourly sweat losses during exercise and to avoid consuming fluid at greater rates during endurance events. This can be facilitated by serial measurements of body weight during and after exercise in a variety of conditions with a goal of maintenance of or a slight reduction in body weight.",
"      <br/>",
"      <br/>",
"      However, the results during training may not be replicated during the race when ADH secretion may not be suppressed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"       8",
"      </a>",
"      ], and may be less likely to be followed by casual athletes who are at higher risk of hyponatremia (eg, race time greater than four hours was a significant risk factor in the 2002 Boston Marathon) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"       1",
"      </a>",
"      ]. Furthermore, the body protects the plasma sodium, not body weight, during exercise, and drinking according to thirst appears to provide sufficient protection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8,66\">",
"       8,66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Second International Exercise-Associated Hyponatremia Consensus Development Conference recommended that race directors record the pre-race weight so that it is available for medical personnel if it is required for comparison to post-race weight [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Sports Medicine (ACSM) has recommended an intake of 500 to 700 mg of sodium (22 to 30 meq) per liter of water ingested as the appropriate level of sodium intake to replace the sodium lost in sweat during endurance events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/29\">",
"     29",
"    </a>",
"    ]. However, there is insufficient evidence that ingestion of sodium prevents or decreases the risk of EAH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/67,68\">",
"     67,68",
"    </a>",
"    ] and consumption of",
"    <span class=\"nowrap\">",
"     carbohydrate/electrolyte",
"    </span>",
"    containing sports drinks does not provide much protection, since most of these drinks are markedly hypotonic to plasma, although they contain roughly the same concentration of cation (sodium plus potassium) as recommended by the ACSM [",
"    <a class=\"abstract\" href=\"UTD.htm?1/42/1706/abstract/1,8,23\">",
"     1,8,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'High fluid intake'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=see_link\">",
"       \"Patient information: Hyponatremia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise-associated hyponatremia (EAH) primarily occurs in athletes participating in endurance events, such as marathons, triathlons, and ultradistance races. The incidence of EAH in such events was 6 percent in a large review but has varied among individual studies, ranging from 0 to 51 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major risk factor for EAH is a high rate of fluid consumption during and after exercise that is typically associated with weight gain compared with the pre-race weight. Other independent risk factors include longer race time (or the related variable of slower training pace), low body mass index, and in some studies, the use of nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluid intake in excess of fluid loss is the primary pathogenic mechanism underlying EAH. Although excessive fluid consumption is necessary, it is not the sole explanation in many cases of EAH. The other major factor is impaired urinary water excretion due to persistent secretion of antidiuretic hormone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of hyponatremic athletes are asymptomatic or mildly symptomatic, with manifestations such as weakness, dizziness, headache, nausea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting. These athletes usually have serum sodium concentrations ranging from 128 to 134",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Severe manifestations of seizures, obtundation, and coma occur primarily in athletes with a serum sodium concentration &le;132",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend direct measurement of the serum or plasma sodium in any endurance athlete with signs or symptoms compatible with hyponatremic encephalopathy, including seizures, obtundation, and coma. If the sodium concentration cannot be measured at an endurance event, a presumptive diagnosis of EAH can be made if an athlete presents with severe central nervous system manifestations consistent with acute hyponatremia in the absence of an obvious alternative etiology. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of EAH should",
"      <strong>",
"       not",
"      </strong>",
"      be assumed in the \"collapsed athlete\" without measurement of the serum or plasma sodium since hyponatremia is present in only a small proportion of these individuals and hypernatremia is more common and would be made worse with hypertonic saline therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'The collapsed athlete'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment recommendations are based upon the limited data from small, uncontrolled case series, our current understanding of the pathogenesis of hyponatremia, and the treatment of hyponatremia in other settings. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among athletes with hyponatremia and",
"      <strong>",
"       mild to moderate",
"      </strong>",
"      symptoms due to EAH (such as weakness, dizziness, headache, nausea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting), we recommend fluid restriction and observation until the onset of a spontaneous diuresis rather than administering hypertonic saline (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This will correct the hyponatremia and lead to resolution of the symptoms. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Mild to moderate symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among athletes with hyponatremia and mild to moderate symptoms due to EAH that seem to be worsening, an intravenous bolus of 100 mL of hypertonic saline is potentially beneficial and without potential harm. We would",
"      <strong>",
"       not",
"      </strong>",
"      give hypertonic saline if the plasma or serum sodium cannot be measured, since hypernatremia is more common than hyponatremia in endurance athletes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Mild to moderate symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among athletes with hyponatremia and",
"      <strong>",
"       severe",
"      </strong>",
"      central nervous system manifestations of hyponatremic encephalopathy (eg, seizures, confusion, coma), we recommend the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypertonic saline should be administered by experienced medical personnel in the field (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest an initial bolus of 100 mL of hypertonic (3 percent) saline, which should raise the serum sodium by 2 to 3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Use of hypertonic saline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the serum or plasma sodium cannot be measured on site, we suggest that this regimen be given empirically by experienced medical personnel to athletes with symptoms compatible with hyponatremic encephalopathy (eg, seizures, confusion, coma) and no other obvious cause (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      All athletes with severe symptomatic hyponatremia should be promptly transported to a hospital for further evaluation and treatment.",
"     </li>",
"     <li>",
"      One or two repeat boluses can be given at ten minute intervals prior to arrival at the hospital",
"      <strong>",
"       only",
"      </strong>",
"      if the plasma or serum sodium has been measured.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous isotonic saline is not necessary in most patients and may",
"      <strong>",
"       worsen",
"      </strong>",
"      the hyponatremia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of EAH has focused upon education concerning the risks of the overconsumption of fluids during the event. Universal guidelines for prevention are difficult since there are wide variations in sweat production and renal water excretory capacity both between individual athletes and in the same individual depending upon ambient conditions during the race. We recommend that, during the race, endurance athletes",
"      <strong>",
"       drink",
"      </strong>",
"      <strong>",
"       according to thirst",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consumption of",
"      <span class=\"nowrap\">",
"       carbohydrate/electrolyte",
"      </span>",
"      containing sports drinks does",
"      <strong>",
"       not",
"      </strong>",
"      provide much protection compared to water alone, since most of these drinks are markedly hypotonic to plasma (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Prevention'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/1\">",
"      Almond CS, Shin AY, Fortescue EB, et al. Hyponatremia among runners in the Boston Marathon. N Engl J Med 2005; 352:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/2\">",
"      Noakes TD, Sharwood K, Speedy D, et al. Three independent biological mechanisms cause exercise-associated hyponatremia: evidence from 2,135 weighed competitive athletic performances. Proc Natl Acad Sci U S A 2005; 102:18550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/3\">",
"      Frizzell RT, Lang GH, Lowance DC, Lathan SR. Hyponatremia and ultramarathon running. JAMA 1986; 255:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/4\">",
"      Sallis, RE. Fluid balance and dysnatremias in athletes. Curr Sports Med Rep 2008; 7:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/5\">",
"      Noakes TD, Goodwin N, Rayner BL, et al. Water intoxication: a possible complication during endurance exercise. Med Sci Sports Exerc 1985; 17:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/6\">",
"      Wyndham CH, Strydom NB. The danger of an inadequate water intake during marathon running. S Afr Med J 1969; 43:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/7\">",
"      Noakes TD. Overconsumption of fluids by athletes. BMJ 2003; 327:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/8\">",
"      Hew-Butler T, Ayus JC, Kipps C, et al. Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med 2008; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/9\">",
"      Davis DP, Videen JS, Marino A, et al. Exercise-associated hyponatremia in marathon runners: a two-year experience. J Emerg Med 2001; 21:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/10\">",
"      Sharwood K, Collins M, Goedecke J, et al. Weight changes, sodium levels, and performance in the South African Ironman Triathlon. Clin J Sport Med 2002; 12:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/11\">",
"      Noakes TD, Norman RJ, Buck RH, et al. The incidence of hyponatremia during prolonged ultraendurance exercise. Med Sci Sports Exerc 1990; 22:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/12\">",
"      Hew TD, Chorley JN, Cianca JC, Divine JG. The incidence, risk factors, and clinical manifestations of hyponatremia in marathon runners. Clin J Sport Med 2003; 13:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/13\">",
"      Montain SJ, Sawka MN, Wenger CB. Hyponatremia associated with exercise: risk factors and pathogenesis. Exerc Sport Sci Rev 2001; 29:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/14\">",
"      Wharam PC, Speedy DB, Noakes TD, et al. NSAID use increases the risk of developing hyponatremia during an Ironman triathlon. Med Sci Sports Exerc 2006; 38:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/15\">",
"      Reid SA, Speedy DB, Thompson JM, et al. Study of hematological and biochemical parameters in runners completing a standard marathon. Clin J Sport Med 2004; 14:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/16\">",
"      Speedy DB, Noakes TD, Rogers IR, et al. Hyponatremia in ultradistance triathletes. Med Sci Sports Exerc 1999; 31:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/17\">",
"      Lebus DK, Casazza GA, Hoffman MD, Van Loan MD. Can changes in body mass and total body water accurately predict hyponatremia after a 161-km running race? Clin J Sport Med 2010; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/18\">",
"      Hew-Butler T, Sharwood K, Boulter J, et al. Dysnatremia predicts a delayed recovery in collapsed ultramarathon runners. Clin J Sport Med 2007; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/19\">",
"      Hoffman MD, Stuempfle KJ, Rogers IR, et al. Hyponatremia in the 2009 161-km Western States Endurance Run. Int J Sports Physiol Perform 2012; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/20\">",
"      Knechtle B, Knechtle P, Rosemann T. Low prevalence of exercise-associated hyponatremia in male 100 km ultra-marathon runners in Switzerland. Eur J Appl Physiol 2011; 111:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/21\">",
"      Verbalis JG. Renal function and vasopressin during marathon running. Sports Med 2007; 37:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/22\">",
"      Siegel AJ, Verbalis JG, Clement S, et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med 2007; 120:461.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/23\">",
"      Dugas J. Sodium ingestion and hyponatraemia: sports drinks do not prevent a fall in serum sodium concentration during exercise. Br J Sports Med 2006; 40:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/24\">",
"      Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med 2000; 132:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/25\">",
"      Baker J, Cotter JD, Gerrard DF, et al. Effects of indomethacin and celecoxib on renal function in athletes. Med Sci Sports Exerc 2005; 37:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/26\">",
"      Halperin ML, Kamel KS, Sterns R. Hyponatremia in marathon runners. N Engl J Med 2005; 353:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/27\">",
"      Olsson KE, Saltin B. Variation in total body water with muscle glycogen changes in man. Acta Physiol Scand 1970; 80:11.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed. McGraw Hill, New York, 2001, pp 285-296.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/29\">",
"      Rosner MH, Kirven J. Exercise-associated hyponatremia. Clin J Am Soc Nephrol 2007; 2:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/30\">",
"      Speedy DB, Noakes TD, Kimber NE, et al. Fluid balance during and after an ironman triathlon. Clin J Sport Med 2001; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/31\">",
"      Galun E, Tur-Kaspa I, Assia E, et al. Hyponatremia induced by exercise: a 24-hour endurance march study. Miner Electrolyte Metab 1991; 17:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/32\">",
"      Hew-Butler T, Jordaan E, Stuempfle KJ, et al. Osmotic and nonosmotic regulation of arginine vasopressin during prolonged endurance exercise. J Clin Endocrinol Metab 2008; 93:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/33\">",
"      Merry TL, Ainslie PN, Walker R, Cotter JD. Fitness alters fluid regulatory but not behavioural responses to hypohydrated exercise. Physiol Behav 2008; 95:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/34\">",
"      Hew-Butler T, Dugas JP, Noakes TD, Verbalis JG. Changes in plasma arginine vasopressin concentrations in cyclists participating in a 109-km cycle race. Br J Sports Med 2010; 44:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/35\">",
"      Freund BJ, Shizuru EM, Hashiro GM, Claybaugh JR. Hormonal, electrolyte, and renal responses to exercise are intensity dependent. J Appl Physiol 1991; 70:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/36\">",
"      Beardwell CG, Geelen G, Palmer HM, et al. Radioimmunoassay of plasma vasopressin in physiological and pathological states in man. J Endocrinol 1975; 67:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/37\">",
"      van Nieuwenhoven MA, Vriens BE, Brummer RJ, Brouns F. Effect of dehydration on gastrointestinal function at rest and during exercise in humans. Eur J Appl Physiol 2000; 83:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/38\">",
"      Rowe JW, Shelton RL, Helderman JH, et al. Influence of the emetic reflex on vasopressin release in man. Kidney Int 1979; 16:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/39\">",
"      Baylis PH, Zerbe RL, Robertson GL. Arginine vasopressin response to insulin-induced hypoglycemia in man. J Clin Endocrinol Metab 1981; 53:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/40\">",
"      Chiodera P, Coiro V. Endogenous opioid mediation of somatostatin inhibition of arginine vasopressin release evoked by insulin-induced hypoglycemia in man. J Neural Transm Gen Sect 1991; 83:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/41\">",
"      Takamata A, Mack GW, Stachenfeld NS, Nadel ER. Body temperature modification of osmotically induced vasopressin secretion and thirst in humans. Am J Physiol 1995; 269:R874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/42\">",
"      Montain SJ, Laird JE, Latzka WA, Sawka MN. Aldosterone and vasopressin responses in the heat: hydration level and exercise intensity effects. Med Sci Sports Exerc 1997; 29:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/43\">",
"      McConell GK, Burge CM, Skinner SL, Hargreaves M. Influence of ingested fluid volume on physiological responses during prolonged exercise. Acta Physiol Scand 1997; 160:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/44\">",
"      EDELMAN IS, JAMES AH, BROOKS L, MOORE FD. Body sodium and potassium. IV. The normal total exchangeable sodium; its measurement and magnitude. Metabolism 1954; 3:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/45\">",
"      EDELMAN IS, JAMES AH, BADEN H, MOORE FD. Electrolyte composition of bone and the penetration of radiosodium and deuterium oxide into dog and human bone. J Clin Invest 1954; 33:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/46\">",
"      Lindinger MI, Heigenhauser GJ, McKelvie RS, Jones NL. Blood ion regulation during repeated maximal exercise and recovery in humans. Am J Physiol 1992; 262:R126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/47\">",
"      Buono MJ, Ball KD, Kolkhorst FW. Sodium ion concentration vs. sweat rate relationship in humans. J Appl Physiol 2007; 103:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/48\">",
"      Shibasaki M, Wilson TE, Crandall CG. Neural control and mechanisms of eccrine sweating during heat stress and exercise. J Appl Physiol 2006; 100:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/49\">",
"      Buono MJ, Sjoholm NT. Effect of physical training on peripheral sweat production. J Appl Physiol 1988; 65:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/50\">",
"      Yamazaki F, Fujii N, Sone R, Ikegami H. Mechanisms of potentiation in sweating induced by long-term physical training. Eur J Appl Physiol Occup Physiol 1994; 69:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/51\">",
"      Nadel ER, Pandolf KB, Roberts MF, Stolwijk JA. Mechanisms of thermal acclimation to exercise and heat. J Appl Physiol 1974; 37:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/52\">",
"      Speedy DB, Rogers IR, Noakes TD, et al. Exercise-induced hyponatremia in ultradistance triathletes is caused by inappropriate fluid retention. Clin J Sport Med 2000; 10:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/53\">",
"      Speedy DB, Noakes TD, Rogers IR, et al. A prospective study of exercise-associated hyponatremia in two ultradistance triathletes. Clin J Sport Med 2000; 10:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/54\">",
"      Hew-Butler T, Collins M, Bosch A, et al. Maintenance of plasma volume and serum sodium concentration despite body weight loss in ironman triathletes. Clin J Sport Med 2007; 17:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/55\">",
"      Young M, Sciurba F, Rinaldo J. Delirium and pulmonary edema after completing a marathon. Am Rev Respir Dis 1987; 136:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/56\">",
"      Hew-Butler T, Anley C, Schwartz P, Noakes T. The treatment of symptomatic hyponatremia with hypertonic saline in an Ironman triathlete. Clin J Sport Med 2007; 17:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/57\">",
"      Siegel AJ, d'Hemecourt P, Adner MM, et al. Exertional dysnatremia in collapsed marathon runners: a critical role for point-of-care testing to guide appropriate therapy. Am J Clin Pathol 2009; 132:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/58\">",
"      Ellis C, Cuthill J, Hew-Butler T, et al. Case report: exercise-associated hyponatremia with rhabdomyolysis during endurance exercise. Phys Sportsmed 2009; 37:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/59\">",
"      Bruso JR, Hoffman MD, Rogers IR, et al. Rhabdomyolysis and hyponatremia: a cluster of five cases at the 161-km 2009 Western States Endurance Run. Wilderness Environ Med 2010; 21:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/60\">",
"      Ayus JC, Arieff A, Moritz ML. Hyponatremia in marathon runners. N Engl J Med 2005; 353:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/61\">",
"      Adrogu&eacute; HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/62\">",
"      Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009; 29:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/63\">",
"      Cheuvront SN, Haymes EM. Ad libitum fluid intakes and thermoregulatory responses of female distance runners in three environments. J Sports Sci 2001; 19:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/64\">",
"      Speedy DB, Rogers IR, Noakes TD, et al. Diagnosis and prevention of hyponatremia at an ultradistance triathlon. Clin J Sport Med 2000; 10:52.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.usatf.org/groups/Coaches/library/hydration/USATFSelfTestingProgramForOptimalHydration.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/66\">",
"      Hew-Butler T, Verbalis JG, Noakes TD, International Marathon Medical Directors Association. Updated fluid recommendation: position statement from the International Marathon Medical Directors Association (IMMDA). Clin J Sport Med 2006; 16:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/67\">",
"      Noakes T. Sodium ingestion and the prevention of hyponatraemia during exercise. Br J Sports Med 2004; 38:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/42/1706/abstract/68\">",
"      Speedy DB, Thompson JM, Rodgers I, et al. Oral salt supplementation during ultradistance exercise. Clin J Sport Med 2002; 12:279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2290 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1706=[""].join("\n");
var outline_f1_42_1706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High fluid intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264938073\">",
"      Increased fluid intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Persistent secretion of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of exchangeable sodium stores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sweat sodium loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264939620\">",
"      Relation to serum sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      The collapsed athlete",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H955987\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mild to moderate symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Use of hypertonic saline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rate of correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2290|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 1\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/33/2589\" title=\"figure 2\">",
"      Volume regulation of ADH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=related_link\">",
"      NSAIDs: Electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=related_link\">",
"      Patient information: Hyponatremia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_42_1707="Oxygen delivery in anemia";
var content_f1_42_1707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic mechanisms to increase oxygen delivery in anemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mechanisms that increase",
"arterial oxygen content",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased production of erythropoietin &rarr;",
"hemoglobin synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rightward shift of oxyhemoglobin dissociation curve&nbsp;&rarr;",
"increased O2 delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mechanisms that",
"increase cardiac output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased myocardial contractility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased blood viscosity and decreased peripheral vascular resistance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1707=[""].join("\n");
var outline_f1_42_1707=null;
var title_f1_42_1708="Chemo dose adj renal";
var content_f1_42_1708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy agents that may require dose reduction in patients with renal insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Arsenic trioxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capecitabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carboplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cladribine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine (high dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daunorubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epirubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eribulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fludarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyurea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imatinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irinotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lenalidomide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lomustine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melphalan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxaliplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentostatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemetrexed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sorafenib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptozocin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vandetanib",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1708=[""].join("\n");
var outline_f1_42_1708=null;
var title_f1_42_1709="Pulmonary complications of allogeneic HCT - Preengraftment";
var content_f1_42_1709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary complications of allogeneic hematopoietic cell transplantation: Preengraftment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease process",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Useful diagnostic tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lung biopsy needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial pneumonia",
"       </td>",
"       <td>",
"        Mucositis, neutropenia",
"       </td>",
"       <td>",
"        Fever, cough, sputum",
"       </td>",
"       <td>",
"        Usually focal consolidation; becomes diffuse in acute lung injury",
"       </td>",
"       <td>",
"        Broad based cultures; response to empiric antibiotics",
"       </td>",
"       <td>",
"        Generally not",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fungal pneumonia",
"       </td>",
"       <td>",
"        Prolonged neutropenia; exposure to endemic fungi; prior treatment for invasive fungus",
"       </td>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        Focal nodular and consolidative opacities, \"halo sign\"",
"       </td>",
"       <td>",
"        Broad based cultures including BAL; &beta;-D-glucan; Aspergillus galactomannan; response to empiric antifungal therapy",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Aspiration pneumonia",
"       </td>",
"       <td>",
"        Impaired swallowing due to mucositis; opiate therapy",
"       </td>",
"       <td>",
"        Fever, dyspnea",
"       </td>",
"       <td>",
"        Diffuse or focal ground glass or consolidative opacities",
"       </td>",
"       <td>",
"        Cultures are often negative",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Permeability pulmonary edema",
"       </td>",
"       <td>",
"        Aspiration, engraftment syndrome, hyperacute GVHD, sepsis syndrome",
"       </td>",
"       <td>",
"        Fever, dyspnea",
"       </td>",
"       <td>",
"        Diffuse ground glass opacities",
"       </td>",
"       <td>",
"        Normal BNP, normal LV function on echocardiogram",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cardiogenic pulmonary edema",
"       </td>",
"       <td>",
"        Cardiotoxic medications; copious intravenous fluid administration",
"       </td>",
"       <td>",
"        Dyspnea, weight gain, peripheral edema",
"       </td>",
"       <td>",
"        Perihilar opacities in butterfly distribution, septal thickening, pleural effusion, cardiomegaly",
"       </td>",
"       <td>",
"        Elevated BNP; echocardiogram showing reduced LV function",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Engraftment syndrome",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Erythematous maculo-papular rash, fever &gt;38.3, weight gain",
"       </td>",
"       <td>",
"        CT: bilateral ground-glass opacification, hilar or peribronchial consolidation, and thickening of interlobular septa",
"       </td>",
"       <td>",
"        Skin biopsy; BAL to exclude infection",
"       </td>",
"       <td>",
"        Sometimes to exclude other treatable causes, lung biopsy shows diffuse alveolar damage",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hyperacute GVHD",
"       </td>",
"       <td>",
"        HLA mismatch",
"       </td>",
"       <td>",
"        Rash, abdominal cramps, diarrhea, elevated bilirubin",
"       </td>",
"       <td>",
"        Diffuse ground glass consistent with acute lung injury",
"       </td>",
"       <td>",
"        Skin biopsy; BAL to exclude infection",
"       </td>",
"       <td>",
"        Sometimes to exclude other processes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BAL: bronchoalveolar lavage; BNP: brain natriuretic protein; LV: left ventricular; CT: computed tomography; GVHD: graft-versus-host-disease; HLA: human leukocyte antigens; CTPA: computed tomography pulmonary angiogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1709=[""].join("\n");
var outline_f1_42_1709=null;
var title_f1_42_1710="Food allergy school guidelines";
var content_f1_42_1710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    School guidelines for managing students with food allergies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Food allergies can be life threatening. The risk of accidental exposure to foods can be reduced in the school setting if schools work with students, parents, and physicians to minimize risks and provide a safe educational environment for food-allergic students.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family's responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Notify the school of the child's allergies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work with the school team to develop a plan that accommodates the child's needs throughout the school including in the classroom, in the cafeteria, in after-care programs, during school-sponsored activities, and on the school bus, as well as a Food Allergy Action Plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide written medical documentation, instructions, and medications as directed by a physician, using the Food Allergy Action Plan as a guide. Include a photo of the child on written form.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide properly labeled medications and replace medications after use or upon expiration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Educate the child in the self-management of their food allergy including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Safe and unsafe foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Strategies for avoiding exposure to unsafe foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Symptoms of allergic reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - How and when to tell an adult they may be having an allergy-related problem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - How to read food labels (age appropriate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review policies/procedures with the school staff, the child's physician, and the child (if age appropriate) after a reaction has occurred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide emergency contact information.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        School's responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be knowledgeable about and follow applicable federal laws including ADA, IDEA, Section 504, and FERPA and any state laws or district policies that apply.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review the health records submitted by parents and physicians.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Include food-allergic students in school activities. Students should not be excluded from school activities solely based on their food allergy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify a core team of, but not limited to, school nurse, teacher, principal, school food service and nutrition manager/director, and counselor (if available) to work with parents and the student (age appropriate) to establish a prevention plan. Changes to the prevention plan to promote food allergy management should be made with core team participation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assure that all staff who interact with the student on a regular basis understand food allergy, can recognize symptoms, know what to do in an emergency, and work with other school staff to eliminate the use of food allergens in the allergic student's meals, educational tools, arts and crafts projects, or incentives.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Practice the Food Allergy Action Plans before an allergic reaction occurs to assure the efficiency/effectiveness of the plans.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coordinate with the school nurse to be sure medications are appropriately stored, and be sure that an emergency kit is available that contains a physician's standing order for epinephrine. In states were regulations permit, medications are kept in a easily accessible secure location central to designated school personnel, not in locked cupboards or drawers. Students should be allowed to carry their own epinephrine, if age appropriate after approval from the students physician/clinic, parent and school nurse, and allowed by state or local regulations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Designate school personnel who are properly trained to administer medications in accordance with the State Nursing and Good Samaritan Laws governing the administration of emergency medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be prepared to handle a reaction and ensure that there is a staff member available who is properly trained to administer medications during the school day regardless of time or location.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review policies/prevention plan with the core team members, parents/guardians, student (age appropriate), and physician after a reaction has occurred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work with the district transportation administrator to assure that school bus driver training includes symptom awareness and what to do if a reaction occurs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recommend that all buses have communication devices in case of an emergency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enforce a \"no eating\" policy on school buses with exceptions made only to accommodate special needs under federal or similar laws, or school district policy. Discuss appropriate management of food allergy with family.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss field trips with the family of the food-allergic child to decide appropriate strategies for managing the food allergy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow federal/state/district laws and regulations regarding sharing medical information about the student.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take threats or harassment against an allergic child seriously.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Student's responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should not trade food with others.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should not eat anything with unknown ingredients or known to contain any allergen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should be proactive in the care and management of their food allergies and reactions based on their developmental level.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should notify an adult immediately if they eat something they believe may contain the food to which they are allergic.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    More detailed suggestions for implementing these objectives and creating a specific plan for each individual student in order to address his or her particular needs are available in The Food Allergy &amp; Anaphylaxis Network's (FAAN) School Food Allergy Program. The School Food Allergy Program has been endorsed and/or supported by the Anaphylaxis Committee of the American Academy of Allergy Asthma and Immunology, the National Association of School Nurses, and the Executive Committee of the Section on Allergy and Immunology of the American Academy of Pediatrics. FAAN can be reached at: 800/929-4040.",
"    <div class=\"footnotes\">",
"     ADA: Americans With Disabilities; IDEA: Individuals With Disabilities Education Act; FERPA: Family Educational Rights and Privacy Act.",
"    </div>",
"    <div class=\"reference\">",
"     The following organizations participated in the development of this document: American School Food Service Association; National Association of Elementary School Principals; National Association of School Nurses; National School Boards Association; The Food Allergy &amp; Anaphylaxis Network.",
"     <br>",
"      Reproduced with permission from: the Food Allergy and Anaphylaxis Network. Copyright &copy; Food Allergy and Anaphylaxis Network.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1710=[""].join("\n");
var outline_f1_42_1710=null;
var title_f1_42_1711="Bronchogenic carcinoma CT VIII";
var content_f1_42_1711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic carcinoma with speckled calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Malignant speckled calcification in a solitary pulmonary nodule, proven to represent a bronchogenic carcinoma by biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_42_1711=[""].join("\n");
var outline_f1_42_1711=null;
